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Abstract 
Advances in genetics have empowered gene therapy as a cancer treatment, 
however there are many challenges to delivering genes specifically to target 
disease sites. Presented here is the development of a new non-viral gene 
delivery vehicle, consisting of branched polyethyleneimine (bPEI) condensed 
plasmid DNA polyplexes encapsulated within a PR_b functionalized stealth 
liposome, for the delivery of genes specifically to α5β1 integrin overexpressing 
cancer cells. This new transfection agent mediated higher gene expression than 
non-targeted stealth liposomes and unencapsulated polyplexes in tissue culture. 
In a liver-metastatic colorectal cancer mouse model, PR_b functionalized stealth 
liposomes outperformed non-targeted stealth liposomes and was able to 
specifically transfect the tumor site while avoiding healthy tissues. In addition, a 
comparative investigation of the transfection mechanism of PR_b functionalized 
nanoparticles, DOTAP/DOPE lipoplexes, bPEI polyplexes and stealth liposomes 
was carried out in DLD-1 cells. Results demonstrated that PR_b functionalized 
nanoparticles were optimally balanced for the transfection of DLD-1 cells with 
high colloidal stability, fast integrin mediated internalization kinetics, caveolae 
mediated uptake and endosomal escape. To further increase the specificity of 
gene expression in cancer tissue, a new therapeutic plasmid DNA (pNF-κB-DTA) 
was developed with expression of Diphtheria toxin fragment-A (DTA) gene 
regulated by the transcriptional activity of NF-κB, which is a transcription factor 
upregulated in cancer. The multi-targeted gene delivery system formed by 
encapsulating pNF-κB-DTA/bPEI polyplexes in PR_b functionalized stealth 
liposomes showed more specific gene expression in cancer cells versus healthy 
cells compared to either individually targeted system. Transfecting cancer cells 
using the multi-targeted gene delivery system resulted in a dose-dependent 
reduction of cellular protein expression and a dose-dependent increase in 
cytotoxicity. Our therapeutic delivery system specifically eradicated on average 
70% of a variety of cancer cells while minimally affecting healthy cells. Moving 
forward, the modular nature of our non-viral delivery vehicle design can facilitate 
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targeting novel pairs of extracellular receptors and upregulated transcription 
factors for applications beyond cancer gene therapy. 
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Chapter 1. Introduction  
 
Cancer continues to be a major health problem worldwide. While early detection 
and prevention measures have improved cancer survival rates, cancers that 
avoid detection until later stages are still associated with a high mortality rate. 
According to a CDC report in 2010, half of the colorectal cancer cases and a third 
of the breast cancer cases were only detected at later stages, when treatment is 
more difficult, despite the availability of screening tests.1 40% of breast cancers 
progress to later stages before detection because of unsuccessful screening.2 In 
the US, one in every two men and one in every three women will be diagnosed 
with cancer over their lifetime according to the American cancer society’s annual 
cancer report for 2013. The report also estimates that in 2013, more than 1.6 
million new cases of cancer will be diagnosed in the US alone. While the push for 
better screening techniques continues, we also require better therapeutic 
strategies to address cancers, especially those that continue to avoid early 
detection. 
Recent advances in genetics have made gene therapy an increasingly viable 
treatment for diseases like cancer. As our molecular and genetic understanding 
of cancer grows, we are poised to move away from traditional non-specific forms 
of cancer treatment, such as chemotherapy and radiation therapy, that are 
associated with harmful side-effects, and specifically target the root causes of 
cancer. Genetic therapies can be designed such that therapeutic gene 
expression is promoted by factors prevalent only at diseased sites, thereby 
facilitating a target specific therapeutic effect. Exploring the versatile nature of 
genes can therefore aid in the development of novel therapeutic strategies. 
However, although oncology and genetics have taught us how to specifically 
attack cancer cells, a major challenge is to deliver gene based therapeutics to 
their target sites. Genes administered into the living body face many challenges 
before therapeutics success. These include surviving the body’s defense 
mechanism by avoiding detection and elimination by the macrophage system 
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(MPS), recognition of and uptake into target cells, and successful endosomal 
escape and nuclear localization.3 We need efficient gene delivery vehicles that 
can successfully navigate these barriers and transport genes to their sites of 
action. 
Currently, genes can be delivered using viral and non-viral vectors.3,4 Although 
non-viral vectors are not as efficient as viral vectors in terms of transfection, they 
are often more attractive because they are safer, more tunable and easier to 
build.5,6 However, most non-viral vectors are trumped by many of the in vivo 
delivery challenges listed above. Stealth, or polyethyleneglycol incorporated 
(PEGylated), liposomes given their history of successfully solving many such 
problems for traditional chemotherapeutics,7 can be a potential starting point for 
next generation gene delivery vehicles. In addition, the process of self-assembly 
that generates these liposomes is highly tunable and can incorporate biomimetic 
amphiphiles with unique functionalities. The applications of neutral stealth 
liposomes, such as those used to improve delivery of chemotherapeutics, remain 
as yet vastly unexplored as gene delivery vectors. Consequently, the method of 
transfection mediated by such transfection agents is also poorly understood. The 
development and characterization of targeted stealth liposomes as delivery 
vehicles for novel therapeutic genes may be instrumental in advancing gene 
therapy. 
1.1 Scope 
This thesis presents a modular integration of tunable biomimetic amphiphiles and 
versatile genetic components. Much of the present work has been made possible 
by the vast amount of knowledge gathered on liposomes as self-assembled 
chemotherapy delivery vehicles, and the recent advances in genetic technology. 
Targeted neutral stealth liposomes, which have been extensively used in drug 
delivery, have been combined here with plasmid DNA/polymer complexes 
(polyplexes) to create a new gene delivery system. The transfection mechanism 
of this new transfection agent was extensively investigated in vitro. Furthermore, 
a novel transcriptionally targeted therapeutic plasmid was developed to increase 
specificity of gene expression in cancer tissue, and encapsulated within a 
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targeted stealth liposome to generate a multi-targeted gene delivery system. The 
following sections briefly introduce the three chapters that comprise this thesis.  
1.1.1 PR_b functionalized stealth liposomes for targeted delivery to 
metastatic colon cancer  
Chapter 3 presents a new approach in which we fully encapsulate polymer 
condensed DNA into neutral stealth liposomes; thus, the DNA compaction and 
transfection properties of cationic polymers are combined with the colloidal 
stability of the stealth liposome. To date, there has been a minimal amount of 
work reported on encapsulating polyplexes into a stealth liposome and 
characterizing the system. This void in the literature is most likely due to two 
factors. First there is the difficulty of encapsulating a large, condensed plasmid 
DNA particle into the limited internal volume of a 100-200 nm liposome. Second, 
the proximity in size of unencapsulated polyplexes and polyplex containing 
liposomes presents a challenge in their separation and the quantification of total 
DNA in the final preparation. Chapter 3 presents a polyplex encapsulated 
liposome formulation procedure that addresses each of these challenges. 
In order to further increase the specificity of such a delivery system, various 
targeting moieties can be incorporated into the basic carrier. Targeted liposomes 
have been previously used in the delivery of payloads to various disease sites 
including tumors.8–10 However, the benefits of targeting remain controversial. 
Although targeted liposomes reduce non-specific delivery compared to the free 
therapeutic, there remains considerable room for improvement. When 
administered in vivo, targeted delivery vehicles often accumulate at significant 
levels in healthy tissues,9,11–13 potentially causing undesirable toxic side effects. 
Identification of an optimal receptor-ligand pair that allows the delivery vehicle to 
interact with diseased cells expressing high levels of the receptor, and not with 
healthy cells expressing the receptor at a lower concentration, can lead to 
improved specificities of therapeutic delivery. α5β1 integrin is a promising target 
that has been shown to be overexpressed on both cancer cells as well as on 
cancer vasculature, and associated with increased tumorigenicity, malignancy 
and tumor cell invasiveness.14,15 In addition, α5β1 displays elevated expression 
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levels on certain primary cell lines, while its expression is downregulated during 
development.16 Our group has previously designed a targeting peptide PR_b 
based on fibronectin, the native binding ligand for α5β1 integrin. PR_b was 
engineered by combining the RGD binding site and the PHSRN synergy site,17 as 
this combination of sites is specific for binding to α5β1.17,18 PR_b has 
outperformed both fibronectin and RGD in terms of binding cells expressing the 
α5β1 integrin.17 Subsequently, a hydrophobic lipid tail was linked to the PR_b 
peptide to generate a peptide amphiphile. Taking advantage of the tunability of 
the self-assembly process, the PR_b amphiphile was mixed with an appropriate 
combination of other lipids to generate a self-assembled targeted stealth 
liposome. PR_b functionalized nanoparticles previously formulated in our group 
have shown increased in vitro delivery of model payloads when compared to 
non-targeted vehicles19–21. In Chapter 3, the potential of the PR_b functionalized 
stealth liposome as a new transfection agent is investigated in vitro, and for the 
first time its functionality is tested in vivo. 
1.1.2 Investigating transfection mechanism 
In general, in order to design efficient transfection agents without sacrificing 
stability and delivery specificity, it is necessary to better understand their mode of 
action in vitro. Currently, transfection mechanism of targeted PEGylated systems 
and how it differs from those of conventional unmodified transfection agents is 
not well understood. Researchers investigating the characteristics and 
transfection mechanisms of these agents often disagree and provide no 
consensus on the mode of their transfection.3,22,23 It is apparent that different 
transfection agents have a range of effectiveness across different cell lines, but 
reasons behind the differential activity are not clear. One of the factors that may 
play an important role in determining transfection efficiency is the internalization 
pathway utilized by these transfection agents.24 There have been several major 
pathways implicated so far in the cellular uptake of transfection agents, however 
there is no consensus on which is the most effective. 23,25,26 More work is 
therefore needed to characterize these vectors. In Chapter 4, the transfection 
mechanisms of several different transfection agents are investigated; with a focus 
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on understanding targeted PEGylated systems compared to commonly used 
cationic polymer condensed DNA complexes (polyplexes) and cationic lipid 
condensed DNA complexes (lipoplexes). Specifically, we studied how plasmid 
DNA delivered using DOTAP/DOPE based lipoplexes, branched 
polyethyleneimine (bPEI) based polyplexes, stealth liposomes encapsulating 
bPEI polyplexes and PR_b peptide functionalized stealth liposomes 
encapsulating bPEI polyplexes (presented in Chapter 3) transfect DLD-1 human 
colorectal cancer cells. To this end, flow cytometry and confocal microscopy was 
used to dissect the transfection mechanisms of these different transfection 
agents. Also, carefully selected chemical inhibitors previously shown to 
successfully inhibit their respective routes 27,28, were used to identify the major 
internalization routes preferred by each of the transfection agents. Finally, 
combined observations from the transfection and DNA uptake levels, 
internalization rate kinetics, intracellular colocalization, and inhibition of 
endocytosis facilitated in deciphering the transfection mechanisms of the different 
agents investigated. 
1.1.3 Increasing cancer-specific gene expression  
While PEGylation and incorporation of targeting ligands can improve delivery 
efficiency compared to traditional delivery of free therapeutics, these modified 
delivery systems continue to experience significant non-specific uptake by the 
macrophage system (MPS) when administered in vivo.29 Also, many widely 
investigated cancer cell or cancer vasculature receptor targets such as 
integrins,30 the endothelial growth factor receptor 31 and fibroblast growth factor 
receptor32 are appreciably expressed in healthy tissues and vasculature.33–35 
These issues can lead to the same non-specific side effects that targeted therapy 
aims to avoid, and therefore call for further levels of control to minimize off-target 
delivery effects. Gene therapy can help solve the problem of non-specific delivery 
by combining transcriptional and extracellular receptor targeting. Transcriptional 
targeting has been widely investigated and shown to improve specific delivery to 
the target tissues.36,37 Generally, transcriptional targeting involves delivering a 
gene under the control of a tissue specific promoter – allowing gene expression 
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in target tissues while avoiding healthy tissues. Multi-targeting by combining 
receptor targeting and transcriptional targeting has been shown before to 
effectively increase the specificity of a viral gene delivery system,38–40 however it 
has not yet been sufficiently investigated in a non-viral delivery system before.41 
NF-κB is a well-characterized family of transcription factors that is upregulated in 
a variety of diseases including cancer42 and that is known to mediate resistance 
to chemotherapy and radiation therapy.43 Inhibition of NF-κB activity has been 
shown to improve cancer therapy by reducing NF-κB mediated chemotherapy 
resistance.44 However, its transcriptional activity has never been used as a 
therapeutic target before. Given the central role played by NF-κB as a 
transcription factor controlling a variety of cancer progression pathways, we 
hypothesized its upregulated activity would be sufficient to mediate a therapeutic 
response specifically in cancer cells. In Chapter 5, we present the development 
of a multi-functional therapeutic system wherein a NF-κB responsive 
transcriptionally targeted plasmid was condensed with bPEI and encapsulated in 
a PR_b functionalized stealth liposome. The increased transcriptional activity of 
NF-κB in cancer tissue was used to mediate therapeutic gene expression 
specifically in cancer cells. Also, targeting the transcriptional activity of a single 
upregulated transcription may improve control and outcome predictability 
compared to conventional transcriptional targeting that utilizes entire promoter 
sequences of upregulated genes. This idea is further discussed in Chapter 5. In 
addition, to address the problem of low gene expression mediated by most 
transcriptional targeting, the highly potent diphtheria toxin fragment-A (DTA) was 
chosen as the protein product of gene expression. DTA consists of only the 
catalytic fragment of diphtheria toxin and lacks a cell-penetrating domain, 
minimizing any bystander cell killing effect at off-target sites. A few molecules of 
DTA can be enough to result in cell death through inhibition of protein 
expression45 and DTA-encoding plasmids have been previously used to 
successfully kill cancer cells.36,46 By targeting two well-recognized cancer 
markers, α5β1 integrin and upregulated NF-κB transcriptional activity, a general, 
modular platform for cancer-specific transfection agents was created.
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1.2 Organization of thesis 
In this thesis, the development of a new stealth liposome based transfection 
agent targeted to cancer tissue is presented. To start off, Chapter 2 presents 
useful background information to introduce topics presented in the subsequent 
chapters. Following, in Chapter 3, the challenges in formulating a liposomal gene 
delivery system are outlined, and steps taken to overcome them are presented. 
The optimization and characterization of gene delivery efficiency both in in vitro 
tissue culture as well as in a metastatic tumor mouse model is then discussed. 
Subsequently, the transfection mechanism of the newly formulated transfection 
agent is investigated in Chapter 4, and compared to the mechanisms of other 
commonly used non-viral transfection agents. Observations discussed in this 
chapter can help improve the design of transfection agents in general. In Chapter 
5, the development of a new transcriptionally targeted therapeutic plasmid is 
presented. The newly developed plasmid was encapsulated in the transfection 
agent formulated in Chapter 3, thereby creating a new multi-targeted gene 
delivery vector. The multi-targeted system was tested for improvements in 
specificity of gene expression in cancer cells. Also, the therapeutic effect 
mediated by the multi-targeted system was investigated using a variety of 
techniques in multiple cancer cell lines. The results presented in Chapters 3-5 
can advance liposomal gene delivery and aid in the development of more specific 
gene delivery vectors. 
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Chapter 2. Background 
 
In this section, background information is provided on several key topics that are 
vital to the discussion that follows in subsequent chapters. The development of 
liposome technology and its application in cancer treatment is discussed. The 
benefits of incorporating polyethyleneglycol (PEG) and targeting ligands on the 
surface of delivery vehicles are also presented, with a focus on targeting α5β1 
integrin. Subsequently the basis of gene therapy is presented with an emphasis 
on transcriptional targeting using the upregulated transcriptional activity of NF-
κB. This is followed by a discussion of the need for gene delivery vehicles, a brief 
history of their development and the state and functional properties of commonly 
used transfection agents. This chapter concludes with a discussion of the various 
cell internalization routes involved in the uptake of transfection agents.  
2.1 Liposome technology 
Liposomes are bilayered lipid vesicles often consisting of synthetic derivatives of 
naturally occurring lipids. Hydrophilic payloads can be encapsulated within the 
aqueous vesicle core and hydrophobic payloads are embedded in the lipid 
bilayer. Liposomes were suggested as a carrier for small molecule drugs shortly 
after their development in the early 1960’s,47 and was first approved by the 
Federal Drug Administration for clinical use in the mid 1990’s. Therapeutic 
encapsulated liposomes circulate in the blood for a longer time, and release the 
payload at a slower rate resulting in lower peak levels of drug in the 
bloodstream.48,49 Free drug may be cleared from the bloodstream with half-lives 
as low as 5 min, while liposome encapsulated drugs have half lives in the order 
of 30 to 60 min. Prolonged presence of drugs in the bloodstream can increase its 
therapeutic effect, and this phenomenon is further discussed in section 2.1.2a 
below.  
In addition to a longer clearance time, a more favorable tissue distribution of 
liposome encapsulated therapeutics compared to freely administered 
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therapeutics also contributes to fewer toxic side effects. The relative bulkiness of 
the liposomes prevents extravasation into non-cancerous tissue, but allows 
passage into tumor tissue (section 2.1.1a Passive targeting and the EPR effect). 
Briefly, tumor endothelium has wider fenestrations compared to normal tissue 
allowing bigger particles such as liposomes to pass through and is a prospective 
passive target for cancer treatment. Through this effect, liposomes protect some 
normal tissues from being subjected to potentially toxic cancer therapeutics. 
Liposome encapsulation has been experimentally and clinically proven to reduce 
toxic side effects of therapeutics.50,51  
2.1.1 Self assembly and the formation of liposomes 
Liposomes are prepared from a variety of amphiphilic lipids or lipid mixtures, the 
most commonly used being phospholipids. Phospholipids, like all other 
amphiphilic compounds, consist of a polar head group and a hydrophobic tail 
group. In an aqueous environment, these amphiphilic molecules self-assemble 
into various structures through a hydrophobic effect that maximizes the entropy 
of the surrounding water molecules.52 The final self-assembled structure formed 
by such amphiphilic compounds in an aqueous environment primarily depends 
on the shape of the individual molecules; the final shape of the self-assembled 
structure can therefore be controlled by using differently shaped monomers. 
Cylindrical double tailed amphiphilic molecules that have been shown to form 
lipid bilayers can assemble into bilayered vesicles, liposomes. The general 
structure of such a phospholipid, 1,2 Dipalmitoyl-sn-Glycero-3-Phosphocholine 
(DPPC), is shown in Fig. 1. 
Tuning the original lipid mixture can control the properties of the liposome 
formed; thus it is important to monitor the lipid ratios used to ensure success of 
the liposome in its intended application. In addition to the basic requirement of 
cylindrical molecules, constituent lipids should be chosen based on phase 
transition temperature and effect on overall permeability, fluidity and stability of 
the liposome. Liposomes undergo a phase transition at temperatures higher than 
a critical temperature Tc where the membrane becomes fluid like with increased 
permeability and reduced mechanical strength. For in vivo applications, this is 
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undesirable as it can lead to liposome degradation or leakage of therapeutic 
loads.7 Based on these criteria, our group commonly uses lipids such as DPPC 
and cholesterol. DPPC is the main liposome-forming lipid, while cholesterol is 
used as a strengthening agent. It has been shown that incorporation of 
cholesterol in greater than 33% inhibits phase transition, and reduces fluidity and 
permeability of the liposome membrane.53 
 
Figure 1. 1,2 Dipalmitoyl-sn-Glycero-3-Phosphocholine (DPPC).  
Color codes for the different atoms are: Carbon (green), Hydrogen (white), Phosphorus 
(purple) and Oxygen (red). [Adapted from Avantipolar lipids] 
 
Depending on the method of preparation of liposomes a variety of vesicle 
structures can result. The most common of these are multilamellar vesicles 
(MLV), small unilamellar vesicles (SUV) and large unilamellar vesicles (LUV). 
Depending on the particular application that the liposomes are intended for, one 
of these formulations may hold an advantage over the others.7 Multilamellar 
vesicles are large and possess a low internal aqueous fraction, as the lamellar 
lipids take up most of the space. SUVs and LUVs both have a single outer lipid 
shell, the amount of internal aqueous cores being different as a result of their 
different sizes.  For the encapsulation of aqueous loads the unilamellar vesicles 
are more desirable, while multilamellar vesicles are more useful for hydrophobic 
loads. The liposome size is a crucial factor determining in vivo fate of the delivery 
system. Liu et al. showed tumor accumulation is highest for liposomes in the 
range 100-200nm.54 Below 100nm, liposomes are preferentially taken up in the 
liver, and much beyond this size accumulation in the spleen starts increasing. 
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Good therapeutic delivery systems need to evade capture in the liver, spleen and 
the rest of the MPS while specifically reaching the target tissue.54  
Although liposomal drug encapsulation showed early promise, there remained 
some unaddressed concerns. The exposed outer surface of these “bare” 
liposomes make them vulnerable to unfavorable interactions with serum proteins 
called opsonins. This opsonization process attracts macrophages and 
encourages phagocytosis of bound liposomes. Detection and elimination by the 
macrophage system (MPS) constitute key steps in the body’s defense 
mechanism against unwanted foreign invaders. Intercalation of plasma proteins 
on the liposome surface also destabilizes the lipid bilayer causing the liposomes 
to break apart and release the encapsulated material.55,56 Both opsonization and 
destabilization remove the liposomes from the blood stream, making them 
unavailable for the target tissue. In order to make liposomal drug delivery a 
success, new strategies were needed to increase liposome circulation lifetime in 
the blood by increasing their stability and decreasing their interactions with 
plasma proteins. 
 
Figure 2. Evolution of liposomes as therapeutic delivery vehicles  
[Liposome images credited to R. Levine]. 
 
2.1.2 Stealth liposomes 
The evolution of liposomes as drug delivery vehicles is depicted in Fig. 2. 
Incorporation of polyethyleneglycol (PEG) on the surface of liposomes was 
suggested as a means to inhibit MPS clearance. The PEG layer on the liposome 
surface is believed to provide a steric barrier against protein adsorption,57,58 and 
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thereby increased the liposome blood circulation lifetime to a half life of greater 
than 5 h compared to 30 min for conventional liposomes.59,60 The term “Stealth 
liposomes” was coined to describe these long circulating PEGylated liposomes. 
Stealth liposomes are believed to be more successful than conventional bare 
liposomes due to its increased circulation lifetime, which in turn has been 
correlated to increased accumulation in the tumor tissue.61 The increased 
circulation lifetime of drug encapsulated liposomes is especially beneficial for 
those drugs that require prolonged exposure for increased efficiency.62,63 As 
discussed below, an increased circulation lifetime of stealth liposomes makes 
them better suited to enhanced permeation and retention (EPR) mediated tumor 
accumulation. 
 
 
Figure 3. Enhanced permeation and retention effect.  
In healthy tissues (A), normal fenestrations allow only smaller particles to escape the 
vasculature. Any left over particles in the tissues are then efficiently cleared out by the 
lymphatic drainage system. However, in tumor tissue (B), irregular blood vessel 
architecture with large fenestration enables large particles 100-200nm in diameter to 
escape into tissues. In addition, lack of proper lymphatic drainage results in prolonged 
tissue retention. Therapeutic delivery systems can use this effect to passively accumulate 
in tumor tissue. 
 
2.1.2a Passive targeting and the EPR effect 
Particle escape from the circulation occurs at locations in the vasculature with 
wider gaps or fenestrations, or with inflammation-induced abnormal endothelial 
barriers. Tumor vasculature is often characterized by a highly irregular 
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architecture with large fenestrations in the endothelial layer, increased vessel 
tortuosity and abnormally heterogeneous vessel density,64 and is therefore 
associated with enhanced permeability, as depicted pictorially in Fig. 3. Several 
studies demonstrated that 100-200nm sized liposomes can successfully 
extravasate into tumors in experimental animals and humans.7,54,65 In addition 
tumor tissue has high fluid retention due to the lack of lymphatic drainage; hence 
any liposomes that extravasate out from the vasculature into the tumor are 
retained. Together, this enhanced permeability and retention (EPR) effect in 
tumor tissues form the basis of the passive targeting of liposomes. The EPR 
effect can cause increased accumulation in the tumor tissue, but it is a slow 
process that can occur over days.66 For this reason, long circulation lifetime is a 
crucial requirement for successful delivery. To improve the rate of tumor delivery 
of passively targeted stealth liposomes, active targeting strategies were required. 
2.1.3 Actively targeted delivery 
In the nineteenth century Paul Ehrlich first presented the concept of a magic 
bullet, a system to deliver therapeutic loads only to the specific diseased area 
while sparing the rest of the body. Two of the ways this could be achieved is by 
using site-specific or site-triggered delivery systems. Site-specific drug delivery 
involves the incorporation of targeting moieties on the surface of delivery 
vehicles, enabling these vehicles to selectively bind to target cells. Site-triggered 
delivery is designed to initiate payload release from delivery vehicles upon 
encountering conditions that prevail only in the target tissue such as temperature, 
pH or the presence of a particular enzyme. In this section we will primarily 
discuss the former of these two targeting strategies. The idea behind site-specific 
delivery revolves around two major concepts – identification of a good target and 
selection of a corresponding targeting ligand, and each of these is discussed in 
some detail below. 
2.1.3a Identification of optimal targets- α5β1 integrin 
Cancer tissue is often distinguished from healthy tissue by the relative expression 
levels of molecules on the cell surface. Such a situation is illustrated in Fig. 4. A 
good cancer-specific target needs to be expressed at a higher level in cancer 
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tissue relative to healthy tissue and be accessible from the blood circulation. Cell 
adhesion molecules (CAMs) are a class of cell surface receptors that have been 
shown to be involved in many diseases including cancer.67–70 Integrins, a 
subgroup of CAMs, are transmembrane glycoproteins involved in a wide range of 
cell adhesion interactions, and exist as non-covalent heterodimers of α and β 
polypeptide chains. There have been 18 α subunits and 8 β subunits identified so 
far in mammalian cells, and these can heterodimerize into at least 20 different 
integrins.71 Out of these, α5β1 integrin is one of the promising targets that has 
been shown to be overexpressed on both cancer cells as well as on cancer 
vasculature, and minimally expressed on normal healthy tissues, and associated 
with increased tumorigenicity, malignancy and tumor cell invasiveness.14,15 In 
addition, α5β1 is also expressed on certain primary cell lines, but its expression is 
downregulated during development.16 α5β1 integrin has therefore been widely 
investigated for the cancer-specific delivery of both chemotherapeutics and 
genes. 
 
Figure 4. The concept of receptor targeted delivery.  
Cancer cells often overexpress certain receptor molecules on their surface compared to 
healthy cells. Designing therapeutic delivery systems to recognize these surface markers 
can ensure specificity of delivery to cancer cells. 
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2.1.3b Identification of efficient targeting ligands – PR_b peptide 
Targeting ligands, like in vivo targets, need to fulfill certain criteria to ensure 
efficient targeted therapeutic delivery. Primarily, we need these targeting ligands 
to be able to bind the in vivo targets with specificity and high affinity. In addition, 
these ligands need to be biocompatible, non immunogenic and demonstrate in 
vivo stability. Peptides can potentially meet many of these criteria and have 
therefore been investigated as targeting ligands for therapeutic delivery to 
various disease sites.10 
Peptides consisting of the Arginine-Glycine-Aspartate (RGD) sequence are 
known to be potent ligands for integrin receptors.72 RGD forms the active binding 
site in fibronectin, which is a native binding protein for integrins (Fig. 5A). RGD 
based peptide sequences have been previously shown to inhibit cancer 
progression.73,74 Although high doses of RGD were initially required to achieve a 
therapeutic effect, numerous developments in RGD based targeting have since 
lowered the required dosage.75–77 Liposomes functionalized with RGD analogs 
were shown to successfully prevent metastasis in an experiment mouse model of 
lung cancer.78 
   
Figure 5. Design of PR_b.  
(A) The fibronectin protein, part of which is shown here, specifically binds α5β1 integrin 
through an RGD binding domain (red) and a PHSRN synergy site (blue) [Adapted from 
Tirrel et al.]. 79 (B) A fibronectin mimetic peptide amphiphile, PR_b, was created by 
artificially joining the RGD binding site and the PHSRN synergy site through a linker (SG5) 
that mimics the natural linking sequence in fibronectin in terms of both length as well as 
hydrophobicity. A KSS spacer was included to extend the PR_b peptide away from an 
anchoring surface. 
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Despite these initial victories of the RGD sequence, its binding affinity for 
integrins is lower than fibronectin, and it binds a range of integrins without 
specificity for any one receptor.80,81 A synergistic amino acid sequence found in 
fibronectin, Pro-His-Ser-Arg-Asn (PHSRN), was found to be important in 
mediating strong cell adhesion.82 Subsequently, many peptides were designed 
linking the RGD binding domain to the synergy PHSRN site, but none of these 
fibronectin mimetic peptides were able to attain the same cell binding properties 
as fibronectin. A few years back our group hypothesized that in order to achieve 
the same binding properties as fibronectin, the peptide region linking the RGD 
and PHSRN sites should mimic the native linker region in fibronectin in both 
length as well as hydrophobicity.83 Based on these criteria a peptide with the 
sequence KSSPHSRNSGSGSGSGSGRGDSP was designed (Fig. 5B), with five 
repeats of Serine-Glycine (SG) linking RGD to PHSRN and a Lysine-Serine-
Serine (KSS) spacer at the amine terminus. This new sequence, named PR_b, 
was able to preferentially bind to α5β1 integrin,17,18 and was found to outperform 
other RGD based sequences as well as native fibronectin in terms of cell 
adhesion.17 As depicted in Fig. 6, a C-16 dialkyl lipid group was attached to the 
N-terminus of the PR_b peptide to generate a biomimetic peptide amphiphile 
which, in combination with other lipids and cholesterol, could self-assemble into 
targeted liposomes.17,19 PR_b functionalized vehicles previously formulated in our 
group have shown increased in vitro delivery of model payloads when compared 
to non-targeted vehicles.19–21 In Chapter 3, we investigate the potential of the 
PR_b functionalized stealth liposome as a new transfection agent in vitro, and for 
the first time test its functionality in vivo. 
 
Figure 6. PR_b peptide amphiphile 
A C-16 dialykl lipid group was attached to the N terminus of the PR_b peptide to generate 
an amphiphile. 
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2.2 Gene therapy 
The genetic code regulates the behavior of all cells, and therefore of entire 
organisms. All the information to propagate and maintain life lies in the specific 
sequence of nucleotides that make up genes. Given the recent technological 
advances in the biomedical field and increased knowledge about the human 
genome, we now know the genetic basis of many diseases, and can target these 
deficit genes as a means to cure disease. Basically, gene therapy involves 
introduction of genetic material into a host cell with an end goal of achieving a 
therapeutic effect, often through the production of a therapeutic protein.  
 
Figure 7. Basic concepts in gene expression 
2.2.1 The central dogma 
In mammalian cells, genes are decoded in the nucleus and used to synthesize 
messenger ribonucleic acid (mRNA) by a process called transcription.84 As 
depicted in Fig. 7, transcription factors bind to the promoter region upstream of 
genes to be transcribed and recruit RNA polymerase. RNA polymerase then 
moves along the DNA strand and creates an mRNA molecule that matches the 
genetic code being transcribed. At the end of the transcription process, mRNA 
undergoes post-transcriptional modification and is transported out of the nucleus 
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into the cytoplasm where the message is translated into peptide sequences. In 
this process, ribosomes bind mRNA and recruit transfer-RNA (tRNA), which in 
turn forms a chain of amino acids based on the mRNA sequence. The 
polypeptide chains thus formed undergo further post-translational modification 
and possible combination with other polypeptide chains to form proteins. These 
proteins are designed to carry out a variety of functions and thus implement the 
instructions encoded in the genetic sequence.  
2.2.2 Plasmid biology 
In order to carry out a specific function in cells or tissues, genes encoding 
proteins with the appropriate functional properties can be artificially introduced  
 
Figure 8. Common constituents of a generic expression plasmid 
into a target cell. Plasmids, circular DNA of bacterial origin, are often used for 
such purposes. As depicted in Fig. 8, in general plasmids consist of a few basic 
functional genetic components, which include a bacterial origin of replication 
(ORI), an antibiotic resistance gene and its associated promoter, and finally at 
least one gene of interest and its associated promoter. The bacterial ORI and 
antibiotic resistance help in the proper amplification and production of the 
plasmid in bacterial cultures. In addition to these basic components listed here, 
plasmids may comprise additional components for further functions not 
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associated with basic maintenance. Often a mammalian ORI may be included to 
facilitate propagation of the plasmid in mammalian cells.  
The promoter regions for the gene of interest can strongly influence the level of 
gene expression. Promoters vary in strength, and can be broadly classified as 
constitutive and tissue-specific. Constitutive promoters ubiquitously regulate gene 
expression. CMV or CAGS are examples of strong constitutive promoters that 
are commonly used in the design of many plasmids. In contrast, tissue-specific 
promoters, as the name suggests, are only active in certain target sites. This 
offers an opportunity to artificially regulate gene expression in a target-specific 
manner by introducing plasmids bearing a gene of interest under a target-specific 
promoter. This approach is termed transcriptional targeting.  
2.2.3 Transcriptional targeting 
The expression level of a single protein varies between tissues and can be 
regulated at the transcriptional or translational levels. Since gene therapy can 
often be used to transcriptionally control the expression level of a desired protein, 
this section aims to provide some background on transcriptional regulation. 
Transcriptional targeting utilizes promoters that are tissue specific or 
exogenously activated, and examples of each type have been reviewed 
extensively by Robson and Hirst.85 In order to limit gene expression to a specific 
desired location, such as tumors, promoters that are specific to tumor tissue or 
tumor environment can be used.85 Fig. 9 pictorially explains the concept of 
transcriptional targeting. Transcriptional targeting of genes can achieve a level of 
specificity unattainable by conventional small molecule therapeutics. Similar to 
extracellular targets and optimal targeting ligands discussed in Section 2.1.3, 
optimal tissue-specific promoters are also selected based on certain criteria. 
Promoters chosen for transcriptional targeting need to be sufficiently active to 
facilitate a therapeutic effect at the target site and should mediate minimal leaky 
expression elsewhere. Some transcriptionally targeted  
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Figure 9. The concept of transcriptional targeting.  
Panels 1 and 2 indicate two different cell lines with different active transcription factors 
resulting in differential levels of gene expression. In Panel 1, showing a target cell, 
transcription factors X, Y and Z are all active and can initiate transcription of both Gene A 
and Gene B. In Panel 2, showing a non-target cell, transcription factor Y is absent, and 
Gene A is not transcribed. In the design of a transcriptionally targeted therapeutic 
plasmid, shown in Panel 3, the promoter for Gene A can be used to drive the expression 
of a therapeutic gene in the target cell but not in the non-target cell (3A). Furthermore, the 
promoter region can be trimmed to a minimum sequence that is regulated by a single 
essential transcription factor (3B). 
 
promoters that have been successfully used in tumor therapy include the Rad51 
promoter for prostrate cancer,36 H19 for bladder cancer,86 and hTERT promoter 
for generic cancer.37 
2.2.4 Transcription factors and NF-κB 
Promoters, including target specific promoters, are regulated by transcription 
factors. These transcription factors are differentially active in different tissues. 
Consequently, there are several transcription factors that are specifically 
upregulated in cancer tissue and play a central role in disease progression. In 
fact, many oncogenes encode transcription factors and many oncogene-related 
signaling pathways converge on transcription factors. These transcription factors 
in turn regulate oncogene networks that propagate the disease state.  
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NF-κB is a well-characterized family of transcription factors that is upregulated in 
a variety of diseases including cancer.42 These transcription factors consist of 
homo or heterodimers of at least five different proteins – RelA, RelB, cRel, NF-
κB-1, NF-κB-2. Normal functions of NF-κB include negative feedback of its own 
activity, anti-apoptosis, proliferation and immunity.42 In most healthy cells, most 
NF-κB is present as an inactive dimer form bound to inhibitors of NF-κB (IκBs) in 
the cytoplasm (Fig. 10).42,87 However, in diseases such as cancer, various 
pathways result in the ubiquitination and subsequent degradation of IκBs, thus 
constitutively activating NF-κB and allowing it to translocate to the nucleus where 
it upregulates the transcription of many oncogenes.42 NF-κB promotes 
tumorigenesis by stimulating cell proliferation, inhibiting apoptosis and 
encouraging metastasis and angiogenesis.42 It has been implicated in many 
types of cancer including breast,88,89 liver,90 colon,91,92 gastric,93,94 lung,44,95 and 
prostrate,96 where it is often overexpressed in its activated form thus making it a 
desirable target for transcriptional targeting. A promoter activated specifically by 
NF-κB may therefore limit gene expression to the tumor tissue. NF-κB binding 
sequences in many promoters/enhancers have been well characterized.97 From 
these and other NF-κB binding motifs, consensus sequences have been derived 
98 that can be used in the construction of an NF-κB responsive promoter. 
2.3 A brief history of gene delivery  
An early method of gene delivery was the introduction of naked DNA into the 
system of interest. Although somewhat successful at in vitro cell transfection, this 
method performs rather poorly at in vivo situations. Naked DNA is cleared from 
circulation through enzymatic degradation and liver uptake within minutes, 
severely limiting chances of reaching the target tissue.99,100 To improve the 
pharmacokinetics of DNA, it was recognized early on that some form of 
protective modifications needed to be made. Viral vectors are efficient DNA 
delivery agents, but these systems are immunogenic and are cleared rapidly from 
the circulation.5 Fraley et al. and Wong et al. independently showed for the first 
time in 1980 that liposomes could be used to deliver DNA into cultured 
mammalian cells.101,102  
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Figure 10. Transcriptional activity of NF-kB in cancer.  
A) In healthy cells, most NF-κB remains bound to its inhibitor proteins such as IκBα in the 
cytoplasm and regulates minimal gene expression. B) In cancer cells, IκBα is marked for 
degradation and free NF-κB can translocate to the nucleus and initiate transcription. 
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Association with liposomes was suggested to improve the stability of DNA in 
transfection studies. 
After brief modifications to the liposome formulation to increase transfection 
efficiency, the first in vivo liposomal gene delivery was done in liver cells.103,104 A 
glycolipid targeting ligand was incorporated in the liposome to enable more 
efficient delivery to liver cells.49 However, all these systems used anionic or 
neutral lipid compositions in making the liposomes, and were not very efficient in 
encapsulating the negatively charged DNA. Encapsulation of large DNA 
molecules into liposomes thus became an important technical difficulty in the use 
of liposomes for gene delivery. To address this problem, Felgner and coworkers 
first reported successful high efficiency DNA delivery in cationic liposomes.105 
The positively charged lipids interact directly with the negatively charged DNA 
forming lipid-DNA complexes, and have been shown to efficiently transfect cells 
both in vitro and in vivo.106–109 Unfortunately, clinical trials performed with such 
lipid-DNA complexes failed to demonstrate any decisive clinical benefits.110 Major 
drawbacks of these lipoplexes are the low in vivo stability and short half-life, and 
toxic side-effects both in vitro and in vivo.111–113 Even hydrodynamic injections of 
naked DNA are sometimes preferred over these formulations in clinical trials.114 
Therefore, more work was needed for such systems to achieve their full potential. 
Specifically, it would be useful to concentrate the DNA into a smaller volume to 
allow the application of a higher dose in a stable form. One of the areas that has 
been extensively studied and can be applied to this cause is DNA condensation 
and association with stabilizing lipids. 
2.3.1 DNA condensation  
DNA condensation involves decreasing the volume occupied by a DNA molecule. 
In this process the molecule goes from being in a random coil to a more compact 
state where the volume fractions of solvent and DNA are comparable.115 DNA 
condensation can protect DNA from DNA degrading enzymes, as well as help 
concentrate large amounts of DNA into small volumes to enable efficient 
encapsulation into carrier vesicles. Bloomfield lists the forces behind DNA 
condensation as the unfavorable effects from bending DNA and loss in entropy 
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from separation of DNA and solvent, and the favorable effects of coulombic 
interactions from oppositely charged ions and hydration force.116 DNA 
condensation occurs through condensing or transfection agents, which work by 
increasing the condensation favorable forces and decreasing the unfavorable 
forces.  
2.3.2 Common transfection agents 
Most commonly used transfection agents consist of cationic lipids or cationic 
polymers, and modified versions of them. Polyethyleneimine (PEI) 117,118 for 
cationic polymers and dioleoyl trimethylammonium propane/ dioleoyl 
phosphatidylethanolamine (DOTAP/DOPE) 119 for cationic lipids are some of the 
most widely investigated transfection agents that can condense DNA into small 
particles and mediate efficient transfection in vitro. By varying the ratio of polymer 
or lipid to DNA during the condensation process, the net charge of the resulting 
particles can be controlled. Thus, in addition to protecting DNA from enzymatic 
degradation, the positive charge allows these particles to favorably interact with 
the negatively charged cell membrane and encourage internalization. 
Furthermore, PEI and DOTAP/DOPE each possess properties that allow them to 
escape the endosomal pathway following cell internalization.  
PEI is known to escape endosomes through the proton sponge effect,118 which is 
a consequence of structural configuration and protonation of its constituent amine 
groups. In PEI every third group is an amine, and at physiological pH only every 
fifth amine group is protonated. The amount of amines protonated increase as pH 
decreases: 45% of amines are protonated at pH 5 versus only 20% at pH 7.118 
The increase in protonation has two effects. First, there is increased charge 
repulsion, which can help release DNA from a compact structure. And second, as 
the name of this effect suggests, the increased positive charge attracts 
counterions into the endosomes and the resulting increase in osmolarity 
encourages an influx of water. This osmotic swelling ruptures the endosomes 
and releases the DNA into the cytosol. The transfection efficiency of PEI was 
tested in a range of cell lines and its success was attributed to the proton sponge 
effect.120 
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Cationic lipid-mediated transfection is strongly dependent on the mixtures of 
lipids used. Although cationic lipids such as DOTAP/DOPC can condense DNA 
into lamellar liquid crystalline closed packed structures and facilitate endosomal 
uptake, their transfection efficiencies are generally low due to their inability to 
escape the endosomes.  DOPE, instead of DOPC, in the mixture with DOTAP 
and DNA can initiate a structural transition from lamellar to columnar inverted 
hexagonal phase that is amenable to fusion with anionic endosomal 
membranes.121 The helper lipid DOPE can effectively lower the kinetic barrier to 
lipid fusion. The effective mixing of the cationic lipids and anionic endosomal 
lipids neutralizes electrostatic interactions, destabilizes the endosomal bilayer, 
and releases DNA from its initial compact structure into the cytosol outside.121 
2.3.3 PEGylation and targeting of transfection agents 
Despite possessing advantageous properties that can help mediate efficient gene 
expression in vitro, cationic lipid and cationic polymer based transfection agents 
suffer from several disadvantages in vivo.122 PEI and DOTAP/DOPE have poor 
colloidal stability in serum, and have been shown to cause undesirable toxic side 
effects.123,124 The interaction between these agents and cells is primarily 
mediated by electrostatics and can often lead to non-specific transfection at off 
target tissues. In addition, the high positive charge density of the resulting 
condensed DNA particles can form holes in transfected cells and increase 
membrane permeability thereby reducing cell viability.125 One of the modifications 
suggested to address such challenges is the incorporation of PEG on the surface 
of these transfection agents. PEGylation can increase serum stability by reducing 
opsonization and can reduce non-specific cytotoxicity by shielding some of the 
excess surface positive charge. While the circulation half-life in blood after in vivo 
administration varies from a few minutes to 1 h for polymer or lipid condensed 
DNA particles, the inclusion of PEG on these particles increased half-life to over 
6 h.126 Thus PEGylated transfection agents enjoy some of the same benefits as 
stealth liposomes discussed in Section 2.1.2 above. Unfortunately, PEGylation 
reduces transfection efficiency of both cationic polymer and cationic lipid based 
systems,127,128 by interfering with internalization into cells and endosome escape. 
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For cationic lipid based systems, the incorporation of PEG stabilizes the lamellar 
liquid crystalline phase, hinders fusion with the endosomal membrane and 
prevents subsequent DNA release.128 The incorporation of targeting ligands on 
the surface of these PEGylated particles can increase internalization into target 
cells.129,130 Ko and coworkers successfully increased gene delivery to the brain in 
an in vivo mouse model with a transferrin receptor targeted antibody on a 
PEGylated liposome encapsulated polyplex.130 In order to design transfection 
agents with high transfection efficiencies without sacrificing stability and delivery 
specificity, it is necessary to better understand their mode of action in vitro. 
Currently, transfection mechanism of targeted PEGylated systems and how it 
differs from those of conventional unmodified transfection agents is poorly 
understood. Investigations of the characteristics and transfection mechanisms of 
these agents produce discordant results and offer no consensus on the mode of 
their transfection. 3,22,23 Experiments indicate that the efficiency of transfection 
agents is cell line dependent, but reasons behind the differential activity are not 
clear.131 The internalization pathway utilized by these transfection agents may be 
one factor that plays a significant role in regulating transfection efficiency.24 
2.3.4 Internalization routes of transfection agents and transfection 
mechanism 
Sayed and Harashima recently proposed a useful classification of the various 
internalization routes based on their lipid-raft content, and present a useful review 
of their properties.24 Lipid rafts are defined as dynamic, 10-200nm diameter 
heterogeneous sphingolipid and sterol rich regions on the cell membrane that 
can compartmentalize cellular processes.132 Endocytic pathways can be 
classified as non-lipid raft mediated (clathrin mediated), mixed lipid mediated 
(phagocytosis and macropinocytosis), and lipid-raft mediated (caveolae, flotillin, 
Arf6, GRAF-1 and Rho-A mediated).  
2.3.4a Clathrin mediated endocytosis 
Clathrin mediated endocytosis (CME) is the most widely investigated endosomal 
uptake route. A clathrin coat, which consists of clathrin triskelion proteins 
recruited from the cytosol, is a distinguishing character of these internalizing 
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vesicles. Vesicles that undergo CME can be 200 nm or more in diameter, which 
is compatible with the diameters of most gene delivery vehicles. Clathrin coated 
vesicles fuse with early endosomes, where the acidification process starts. As 
the early endosomes mature into late endosomes the pH continues to drop, 
eventually followed by fusion with the lysosomal degradation compartments. 
Cargo internalized by CME will therefore eventually be degraded unless it can 
escape the endosomal route somewhere along the endosome maturation 
process. Both cationic polymer and cationic lipid mediated DNA internalization 
has been shown to progress through this route in specific cell lines.23,133 The 
polyplexes and lipoplexes presented in these studies, using the proton sponge 
effect and endosomal fusion respectively, were able to effectively escape the 
endosomal pathway. However, studies in other cell lines by Rejman et al.134 and 
Ur Rehman et al.25 demonstrated that CME is not productive for transfection. 
Generally, in order to investigate the role of a particular endocytic route in the 
internalization of cargo, chemical inhibitors known to specifically block the 
appropriate route are used. Chlorpromazine is one of the most widely used 
inhibitors of CME.131,135 However, it should be carefully implemented as high 
concentrations have been shown to be toxic to cells by membrane 
permeabilization and reactive metabolite formation.136,137 
2.3.4b Phagocytosis 
Phagocytosis is involved in the uptake of large particles > 500 nm in diameter.138 
Therefore most transfection agents designed for in vivo tumor delivery being 
smaller than this is not expected to be taken up by phagocytosis at the target 
site, although professional phagocytes patrolling the blood circulation may still 
take them up. Phagosomes consist of mixed lipid domains and their formation is 
dynamin-2 dependent. Inhibitors of dynamin, such as dynasore,139 have therefore 
been suggested to block macropinocytosis. Similar to vesicles internalized by 
CME, phagosomes fuse with endosomes and continue the maturation process to 
late endosomes and lysosomes where their cargo is degraded. Particle shape 
has been shown to have a significant effect on phagocytosis, and is extensively 
reviewed by Hillaireau and Couvreur.140 
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2.3.4c Macropinocytosis 
Macropinocytosis, like phagocytosis, occurs in mixed lipid domains at the cell 
membrane. It can internalize large sections of the cell membrane, and therein lies 
the potential for large volumes of material to be taken up non-specifically. Unlike 
phagocytosis and CME, macropinocytosis is dynamin-2 independent and is 
associated with an increased uptake of the fluid phase and associated fluid 
phase markers.141,142 The fate of macropinosomes is cell line dependent – they 
mature parallel to endosomes in macrophages, HEK293 cells and COS-1 cells, 
while they are recycled back to the cell surface in A531 human carcinoma cells 
and HEP-G2 cells.24,133 Macropinocytosis has been suggested as an 
advantageous uptake route for lipoplexes by some studies, 26,143 while others 
regard it as an inefficient process that leads to minimal transfection.133 Sarkar 
and coworkers reported rottlerin to be a potent and specific inhibitor of 
macropinocytosis.144 While other commonly used inhibitors of macropinocytosis, 
such as amiloride and amiloride related compounds, affect pathways other than 
their intended target, rottlerin at concentrations between 2-3 μM inhibited more 
than 80% of macropinocytosis and less than 25% of receptor mediated 
endocytosis in monocyte derived dendritic cells.144 
2.3.4d Caveolae/lipid raft mediated endocytosis 
Out of the lipid raft mediated endocytic processes, caveolar uptake is the most 
widely studied. Caveolar uptake is distinguishable from all the other lipid raft 
mediated uptake pathways by the involvement of caveolin-1 protein. The fate of 
cargo taken up through caveolae-mediated endocytosis is also cell line 
dependent. 24 In non-endothelial cells caveolar cargo is directed to acidic 
organelles for degradation, while in endothelial cells in vivo cargo may traverse a 
cell via transcytosis. Filipin III has been used on numerous occasions to 
specifically inhibit caveolar uptake.131,134 In contrast to some of the other 
inhibitors of caveolar/lipid-raft mediated uptake such as methyl-β-cyclodextrin, 
filipin III can distinguish between caveolar/lipid raft mediated uptake and the other 
internalization routes.145 While filipin III has been primarily used as an inhibitor of 
caveolar uptake by many researchers, recent evidence suggests that it may also 
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have an inhibitory effect on some of the other lipid raft mediated uptake 
pathways. Consequently, in this thesis, we consider filipin III to mostly block the 
caveolar mediated uptake route, with some possible inhibitory effects on the 
other lipid-raft mediated routes. It is unclear whether caveolar uptake confers any 
advantages to gene expression mediated by transfection agents. Wong and 
coworkers have shown that lipoplexes internalized via this route are degraded in 
the endolysosomal compartments.146 Also, studies with dendrimers and chitosan 
nanoparticles as transfection agents reported similar fate.147–149 In contrast, 
Rejman et al.134 and Ur Rehman et al.25 attributed successful transfection to 
caveolar-mediated endocytosis. It is apparent that such controversial viewpoints 
regarding the fate of internalized cargo exist for most of the internalization 
pathways and transfection agents discussed here.  
Some of the other lipid raft mediated uptake pathways include flotillin, Arf6, 
GRAF-1 and Rho-A mediated routes. These pathways involve several players in 
common with intertwined roles, as extensively reviewed by Doherty and 
McMahon.150 One of the few discernible criteria they have in common with each 
other, as well as with caveolar uptake, is the involvement of cholesterol. 
Unfortunately, they do not have specific chemical inhibitors as yet and are 
therefore hard to differentiate.24 For these reasons, these pathways have been 
broadly referred to as lipid-raft mediated pathways in this thesis.  
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Chapter 3. PR_b functionalized stealth liposomes 
for targeted delivery to metastatic colon cancer 
 
3.1 Summary 
A gene delivery system was designed to carry a payload to integrin 
overexpressing cells. Branched-polyethyleneimine (bPEI) condensed plasmid 
DNA was encapsulated into targeted stealth liposomes, thereby combining the 
condensing and transfection properties of bPEI with the stealth and targeting 
properties of the liposomal carrier system. PR_b was used as a targeting ligand - 
a peptide we designed to bind specifically to the cancer cell surface marker α5β1 
integrin - and such a robust receptor-ligand interaction achieved higher specificity 
than what has been previously reported for targeted delivery systems. In the 
process of formulating the PR_b functionalized gene delivery vehicle, we 
developed a protocol to fully encapsulate condensed DNA in liposomes and 
accurately quantify the total DNA in the system. We demonstrate that compared 
to non-targeted stealth liposomes and non-encapsulated condensed DNA, the 
PR_b functionalized stealth liposomes mediated improved in vitro transfection 
specifically to colon cancer cells overexpressing the α5β1 integrin. Furthermore, 
when administered in vivo to metastatic tumor bearing mice, PR_b functionalized 
stealth liposomes outperformed non-targeted liposomes and delivered genes 
specifically to the tumor site.  
3.2 Introduction 
Advances in genetics have made gene therapy an increasingly plausible method 
of disease treatment, and the search for better and more efficient gene delivery 
techniques continues. Free plasmid DNA faces many challenges in gene therapy 
in vivo: it is rapidly degraded by enzymes in the blood,151 it is limited by low levels 
of cellular uptake and subsequently poor intracellular release, leading to low 
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transfection efficiencies.152 Gene delivery vehicles can overcome these issues by 
protecting the plasmid DNA through compaction and improving the transfection 
efficiency through the use of agents that increase cellular uptake and intracellular 
release.    
Both viral and non-viral methods have been used for delivery of therapeutic 
genes,153–158 the latter being advantageous due to reduced immunogenicity, lower 
toxicity and ease of manufacture.5,6 Non-viral vectors for DNA delivery include 
preparations containing cationic polymers and lipids.119,159 Out of these, 
polyethyleneimine (PEI) has been widely investigated and has shown much 
promise as a transfection agent.160–162 PEI condenses DNA into small particles 
and allows efficient DNA release in target cells by the “proton sponge effect” 
(Section 2.3.2).118,163,164 However transfection by PEI alone has been shown to be 
toxic to cells.123,152 To overcome this problem, PEI has been modified in various 
ways to reduce its toxicity and improve transfection efficiency and 
biocompatibility through conjugation to stabilizing polymers or lipids,165–168 
modifications of PEI linkages,169,170 and inclusion of a targeting moiety to improve  
specificity of delivery.171–173 PEI-DNA complexes have also been encapsulated in 
liposomes, or associated with liposomes to form lipopolyplexes,130,174–176 and 
such association has been shown to increase the transfection efficiency of PEI-
condensed DNA systems.177  
Encapsulating payloads in liposomes holds several advantages over 
conventional administration of free therapeutics. Liposomes with diameters of 
100-200 nm can specifically accumulate in tumor tissue by a passive targeting 
mechanism involving the enhanced permeability and retention (EPR) effect.7,54 In 
addition, the steric effect of a polyethyleneglycol (PEG) brush layer on stealth 
liposomes helps to avoid detection by the macrophage system (MPS) and 
prolongs circulation lifetime.57,58 Briefly, liposomes in this size range are able to 
permeate through the larger membrane fenestrations in tumor blood vessels into 
the tumor tissue. Liposomes much larger may non specifically accumulate in the 
spleen by a filtration mechanism, or be trapped in capillaries in the lung, while 
smaller particles can non specifically permeate into other tissues or experience 
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ineffective steric hindrance leading to a reduced circulation lifetime.54,178,179 In 
order to further increase the specificity of the delivery system, various targeting 
moieties can be incorporated into the basic carrier system. Targeted liposomes 
have been used in the delivery of payloads to various disease sites including 
tumors.8,9,180,181 However, the benefits of targeting remain controversial. Although 
targeted liposomes reduce non-specific delivery compared to the free drug, there 
remains considerable room for improvement. When administered in vivo, 
targeted delivery vehicles often accumulate to significant levels in healthy 
tissues, potentially causing undesirable toxic side effects.9,11–13  
Identification of an optimal receptor-ligand pair that allows the delivery vehicle to 
interact with diseased cells expressing high levels of the receptor, and not to 
healthy cells expressing the receptor at a lower concentration, can lead to 
improved specificities of therapeutic delivery. α5β1 integrin is a promising target 
that has been shown to be overexpressed on both cancer cells as well as on 
cancer vasculature, and minimally expressed on normal healthy tissues,14,15,182 
and  associated with cancer-progression properties.14,183,184 In addition, α5β1 is 
also expressed on certain primary cell lines, but its expression is downregulated 
during development.16 RGD is a peptide that binds integrins including α5β1 
integrin and is probably one of the most widely studied ligands in targeted drug 
delivery. 8,9,11–13 However, RGD targeted delivery systems do not reduce 
accumulation in healthy organs when administered in vivo.9,11–13 Hence there is 
the need to develop better targeting systems capable of achieving increased in 
vivo specificity. Our group has previously designed a targeting peptide PR_b 
based on fibronectin, the native binding ligand for α5β1 integrin by combining the 
RGD binding site and the PHSRN synergy site. This combination of sites is 
specific for binding to α5β1.17,18 PR_b has outperformed both fibronectin and RGD 
in terms of binding cells expressing the α5β1 integrin.17 PR_b functionalized 
vehicles previously formulated in our group have shown increased in vitro 
delivery of model payloads when compared to non-targeted vehicles.19–21,185,186 In 
this study, we investigate the potential of the PR_b targeted liposomal system as 
a new transfection agent in vitro, and for the first time test its functionality in vivo. 
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To date, there has been a minimal amount of work reported on encapsulating 
condensed plasmid DNA into a targeted liposome and verifying specificity of the 
delivery vehicle. This is most likely due to two factors. First is the difficulty of 
encapsulating a large, condensed plasmid DNA particle into the limited internal 
volume of a 100-200 nm liposome. Second, the proximity in size of 
unencapsulated particles and condensed DNA containing liposomes presents a 
challenge in their separation and the quantification of total DNA in the final 
preparation. This chapter presents a DNA encapsulated liposome formulation 
procedure that addresses each of these challenges. 
In this study we encapsulated condensed DNA into PR_b functionalized stealth 
liposomes. We subsequently purified the system and quantified total DNA to 
formulate a vehicle that delivers the desired DNA load specifically to cells bearing 
the α5β1 integrin. We have investigated the ability of cationic polymers poly-L-
lysine (pLL) and branched polyethyleneimine (bPEI) to condense DNA into small 
particles that can be encapsulated into a 200 nm liposome. We also tested the in 
vitro DNA transfection efficiency of these condensing agents in both liposomal 
and non-liposomal forms. We used the most efficient condensing system, bPEI in 
our case, to optimize the concentration of the PR_b targeting moiety on targeted 
stealth liposomes. We demonstrate the superior performance by the PR_b 
functionalized gene delivery system when compared to non-targeted liposomes, 
or unencapsulated condensed DNA, in terms of transfection efficiency and 
targeting specificity in vitro and in a metastatic tumor model in vivo. 
3.3. Materials and Methods 
3.3.1 DNA condensation 
20 µg of plasmid pT2/Cal,187 which encodes the firefly luciferase transgene, 
under transcriptional control of a chimeric CAGS promoter (CMV 
enhancer/chicken beta-actin promoter/chicken beta-globin intron sequence) was 
used in this study. An endotoxin-free stock solution of this plasmid was diluted to 
125 µl in distilled water. The amine to phosphate (N/P) ratio of the DNA:polymer 
mixture was calculated as shown previously.188 Calculated volumes of the 
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condensing agent 22.5 kDa pLL (Sigma Aldrich, Saint Louis, MO) or 25 kDa 
branched PEI (Sigma Aldrich, Saint Louis, MO) to achieve a particular N/P ratio 
were also diluted to 125 µl in distilled water. The condensing agent was then 
added rapidly to the DNA solution followed by rapid pipetting to allow quick 
mixing. The system was then vortexed at the lowest speed for 5 minutes and 
then incubated at room temperature for 30 min. DNA particle size was measured 
by dynamic light scattering (DLS) (Brookhaven Instruments Corporation) and 
zeta potential determined using the PALS zeta potential analyzer (Brookhaven 
Instruments Corporation). 
3.3.2 DNA liposome formulation and characterization 
1,2-dipalmitoyl–sn-glycero-3-phosphocholine (DPPC), 1,2-dipa- lmitoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy (poly- ethylene glycol)-2000] 
(ammonium salt) (DPPE-PEG2000) and cholesterol were purchased from 
Avantipolar Lipids, Inc (Alabaster, AL). Non-targeted stealth liposomes were 
made with 55 mol% DPPC, 35% cholesterol and 5% DPPE-PEG2000. Targeted 
stealth liposomes were made with (55-x) % DPPC, 35% cholesterol, 5% DPPE-
PEG2000 and x% PR_b peptide amphiphile, where x was varied between 1.5 
and 9. The PR_b peptide was purchased from University of Minnesota Genomics 
Center (UMGC), and the peptide amphiphile was made as described 
previously.17,189 All liposomes were made using the thin film hydration method,190 
where the mixture of lipids was deposited on the bottom of a 50 ml round bottom 
flask and dried under a stream of argon followed by overnight incubation in a 
vacuum oven. The films were then hydrated with a solution of condensed DNA in 
DI water and incubated at 45-50 °C in a water bath for 2 h. The resulting 
liposomes were extruded through 200 or 400 nm polycarbonate membranes 
(Avestin, Ottawa, Canada) 11 times with a handheld Liposofast extruder (Avestin, 
Ottawa, Canada). Liposomes were then purified by a 24 h dialysis through a 
1000 kDa cellulose ester dialysis membrane (Spectrum Labs, Rancho 
Dominiguez, CA). Lipid concentration was measured using a phosphorus assay 
as described elsewhere (reagents from Sigma Aldrich).191 PR_b concentration on 
the liposomes was determined by the BCA assay (Thermo Scientific, Waltham, 
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MA) following the manufacturer’s protocol. The PR_b concentration is expressed 
as a mole percentage of total lipid. pT2/Cal plasmid DNA was condensed using 
initially pLL at a N/P ratio of 4 and with bPEI at a N/P ratio of 8 (choices justified 
in section 3.4.1), and encapsulated in liposomes functionalized with 
approximately 5 mol% PR_b (actual concentrations are shown in the figure 
captions) or in non-targeted stealth liposomes. The ZetaPALS Zeta Potential 
Analyzer (Brookhaven Instruments, Holtsville, NY) was used to determine both 
the zeta potential, and diameter (by dynamic light scattering; DLS) of the stealth 
liposomes that encapsulated bPEI condensed DNA at N/P ratio of 8. To further 
characterize the size and shape of stealth liposomes encapsulating condensed 
DNA, cryogenic transmission electron microscope (cryo-TEM) images were 
taken. Briefly, 4 μL of liposome samples dissolved in water were deposited onto 
a lacey formvar/carbon copper grid (Ted Pella) treated for 15 s with glow 
discharge and vitrified in liquid ethane by Vitrobot (Vitrobot parameters: 5 s blot 
time, -1 offset, 3 s wait time, 3 s relax time, 95% humidity). Following vitrification, 
the grid was transferred to a Tecnai G2 Spirit TWIN 20-120 kV/LaB6 
Transmission Electron Microscope. Images were captured using an Eagle 2k 
CCD camera with an accelerating voltage of 120kV. 
3.3.3 DNA quantification 
Plasmid DNA was labeled with cy5 fluorescent dye using the Label IT cy5 DNA 
labeling kit (Mirus, Madison, WI) according to the manufacturer’s protocol. 5% of 
the plasmid DNA used in the DNA condensation process was cy5 labeled. At the 
post hydration stage of liposome preparation, a DNA concentration standard 
curve was generated, which was used to quantify the total DNA in the system 
after the final purification step.  
3.3.4 In vitro transfection 
DLD-1 human colon carcinoma cells (ATCC, Manassas, VA) were cultured in 
T75 flasks using Dulbecco-modified Eagle Medium (DMEM) supplemented with 
10% fetal bovine serum and penicillin-streptomycin to 70% confluence and then 
subcultured into white 96 well plates at 5000 cells/well 24 h prior to transfection. 
All cell culture reagents were purchased from the Invitrogen Supply Center, 
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University of Minnesota. On the day of transfection medium was replenished and 
DNA liposomes (liposomes containing 100 ng of condensed DNA) were added to 
wells in replicates of six and incubated at 37 °C for 40 h. Luciferase expression 
was then measured with the Luciferase Reporeter assay kit (Promega, Madison, 
WI) following the manufacturer’s protocol. Luminescence measured from 
untreated cells was used as the background, and that measured from 100 ng of 
unencapsulated DNA condensed with either pLL or bPEI under the same 
conditions was used as control. 
3.3.5 Effect of PR_b concentration on transfection 
Different PR_b concentrations were used to prepare PR_b functionalized 
PEGylated liposomal films. Each of these films was hydrated using DNA 
condensed with bPEI at an N/P ratio of 8. DNA liposomes were then prepared 
and characterized as described above. DLD-1 cells subcultured in a white 96 well 
plate were transfected using 100 ng of liposomal DNA, and luciferase activity was 
assayed as described above in the in vitro transfection section.  
3.3.6 Specificity of targeting 
DLD-1 cells were seeded in a white 96 well plate at 5000 cells/well and cultured 
overnight. Cells were provided with fresh medium the next day and the plate was 
placed at 4 °C for 30 min to equilibrate before the addition of 4 µg of the 
GRGDSP peptide (UMGC) to each well. Following 30 min incubation at 4 °C, 
bPEI-DNA polyplexes encapsulated in PR_b functionalized stealth liposomes 
were added to each well. The plate was incubated at 37 °C and 5% CO2 for a 
total of 32 h with the addition of 4 µg/well GRGDSP peptide every 8 h to maintain 
a high concentration of free peptide for the purposes of blocking integrin binding. 
As positive controls, the same liposomes were used without GRGDSP blocking. 
All wells received 100 ng DNA, as quantified by the cy5 quantification assay 
described above. At the end of the incubation period, luciferase expression was 
assayed as described above. To demonstrate the binding specificity of the PR_b 
peptide, a scrambled PR_b sequence (ScrPR_b, SGRSGSGSHGGDSGSS-
KSSPNPR), was obtained from the UMGC, and used as an alternate targeting 
ligand on liposomes. DLD-1 cells plated at 5000 cells/well in a white 96 well plate 
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were transfected with PR_b or ScrPR_b functionalized stealth liposomes. In 
parallel, DLD-1 cells were first blocked with 16 µg/well free PRb peptide followed 
by transfection with either the PR_b or ScrPR_b targeted liposomes for 32 h at 
37 oC in the presence of free PR_b added every 8 h. All wells received 100 ng of 
DNA encapsulated in liposomes as quantified by the cy5 quantification assay. At 
the end of this incubation period, luciferase expression was measured as 
described above. 
3.3.7 Toxicity of encapsulated or free bPEI-DNA 
DLD-1 cells were seeded overnight in a clear 96 well plate at 5000 cells/well. 
After a medium change the next morning, cells were treated with 100 ng/well 
bPEI-DNA encapsulated in PR_b functionalized stealth liposomes. For 
comparison, unencapsulated bPEI-DNA was delivered at 100 ng/well. Untreated 
cells were used as the control and medium alone was used as the background. 
After 40 h of incubation at 37 ⁰C, 10 µl WST-1 reagent (Clontech, Mountain View, 
CA) was added to each well and incubated after a gentle shake at 37 ⁰C for a 
further 2 h. Following incubation, the absorbance of the plate was read at 450 nm 
using a Spectramax Plus spectrophotometer (Molecular Devices, Sunnyvale, 
CA). Cell viability is reported as the sample absorbance signals as a percentage 
of the signals from the untreated cells. 
3.3.8 Establishment of hepatic tumors 
Female Balb/c mice were obtained from NIH (Frederick, MD) and maintained 
under specific pathogen-free conditions. All animals were treated according to 
the NIH Guidelines for Animal Care with approval of the IACUC of the University 
of Minnesota. Exponentially growing murine CT26 colon carcinoma cells (ATCC, 
Manassas, VA) were trypsinized, resuspended in Hanks balanced salt solution 
(HBSS), and 1 x 105 viable cells in a volume of 150 µl were injected 
intrasplenically into 4-6 week mice. Animals were administered an 
anesthetization cocktail consisting of ketamine HCl (8 mg/ml; Phoenix Scientific, 
St. Joseph, MO), acepromazine maleate (0.1 mg/ml; Phoenix Scientific), and 
butorphanol tartrate (0.01 mg/ml; Fort Dodge Animal Health, Overland Park, KS). 
A peritoneal incision was made, and cells were directly injected into the spleens 
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of recipient animals. Pressure was applied to the injection site for 3 min, and the 
animals were splenectomized. Cells injected into the spleen in this manner flow 
from the splenic vein into the portal vein and seed into the liver, thus confining 
tumor formation to the liver. The incision site was closed with staples, and the 
animals were allowed to recover.  
3.3.9 In vivo liposomal gene delivery and luciferase imaging 
Animals were injected with liposomal formulations at 2 weeks post-tumor 
injection, with tumor growth determined by measuring the abdominal girth of the 
animal. The three groups investigated were: tumor-bearing mice that received 
non-targeted stealth liposomes, tumor-bearing mice that received PR_b 
functionalized stealth liposomes, and healthy, non-tumor-bearing mice that 
received PR_b functionalized stealth liposomes. Four animals per group were 
injected intravenously via the lateral tail vein with liposomal formulations 
containing 700 ng of pT2/Cal plasmid DNA in a total volume of 0.5 ml. 24 h after 
liposomal injections, expression of luciferase was visualized by in vivo 
bioluminescence imaging using the Xenogen IVIS Imaging Sytem (Xenogen, 
Alameda, CA). Mice were anaesthetized using the cocktail described above, 
followed by an intraperitoneal injection of 100 µl luciferin (Promega) and the 
whole mouse was imaged for bioluminescence 5 min later. Mice were sacrificed, 
livers extracted, and imaged ex vivo in 100 µl PBS containing 100 µl luciferin. 
Luciferase expression is reported as photons emitted per second per cm2.  
3.4 Results and Discussion 
3.4.1 Sizing and zeta potential of condensed DNA particles 
Dynamic light scattering data of condensed DNA particle sizes formed at different 
amine to phosphate (N/P) ratios is presented in Fig. 11. The goal of these 
experiments was to identify the optimal N to P ratio to form small condensed  
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Figure 11. Characterization of polymer condensed DNA.  
DLS size measurement of pLL (A) and bPEI (B) condensed DNA particles at different 
amine to phosphate ratios. Corresponding zeta potential charge measurements for pLL 
(C) and bPEI (D) condensed DNA particles. Values represent the mean ± SD (n =3). 
 
 
DNA particles that can be efficiently encapsulated into a 200 nm liposome, and 
have a net positive charge for better transfection.  pLL condensed DNA particles 
were approximately 100 nm for all the N/P ratios tested, except around 2, where 
large visible aggregates were formed resulting in the increased particle size (Fig. 
11A). As others have suggested before,192 this aggregation happens at N/P ratios 
that result in nearly charge neutral particles which experience no repulsion as 
they come together. This is verified by the zeta potential data presented in Fig. 
11C where the net charge of the particles increases from negative to positive as 
the ratio of the positive polymer is increased and is seen to go through zero 
around an N/P ratio of 2. Similarly, for the bPEI condensed DNA particles, this 
aggregation effect was seen around an N /P ratio of 3, with particles sizes less 
than 100nm for other ratios away from this aggregation zone (Fig. 11B). The zeta 
potential of the particles at these same N/P ratios show similar trends to the pLL 
condensed DNA system, with a net neutral zone occurring around a ratio of 3 
(Fig. 11D). Overall the bPEI particles were seen to be smaller than the pLL  
	   41	  
 
Figure 12. Cryo-TEM image of PR_b functionalized stealth liposomes 
encapsulating bPEI condensed DNA 
 
condensed particles at N/P ratios away from the aggregation ratio. In order to 
obtain small positively charged particles to be encapsulated in liposomes, we 
chose an N/P ratio of 4 for the pLL condensed DNA and a ratio of 8 for the bPEI 
condensed DNA system. 
3.4.2 Characterization of targeted and non-targeted stealth liposomes 
encapsulating condensed DNA 
Unlike many previous gene delivery systems where polyplexes are complexed 
with anionic liposomes, we have encapsulated polyplexes into liposomes 
composed of neutral lipids. In this process, there is no active interaction between 
the polyplexes and the liposomes. Polyplexes in the aqueous phase are 
passively encapsulated into liposomes by a thin film lipid hydration process. 20 
µmol lipid films were hydrated with 20 µg of cationic polymer-condensed DNA. 
After the purification step, where unencapsulated condensed DNA is removed, 
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an average concentration of about 5 µg/ml DNA, corresponding to a 40% 
concentration-based yield, is obtained in the final DNA-liposome formulation. 
Three characteristic stealth liposomes each for PR_b functionalized and non-
targeted formulations, containing bPEI condensed DNA at N/P 8 were analyzed. 
Measured sizes were 204 ± 6 nm with zeta potential of -15.3 ± 0.6 mV for the 
non-targeted stealth liposomes. The size of the PR_b functionalized stealth 
liposomes was 279 ± 51 nm and the zeta potential was -3.1 ± 1.8 mV. Although 
the bPEI-DNA complexes are positively charged, once encapsulated in stealth 
liposomes the system as a whole is close to neutral or slightly negative. The lipid 
bilayer and the PEG layer effectively shield the charge of the encapsulated DNA 
particles. In addition, cryo-TEM images of PR_b functionalized stealth liposomes 
encapsulating bPEI condensed DNA were taken and shown in Fig. 12. These 
images confirm the presence of approximately 100 nm sized condensed DNA 
particles within spherical stealth liposomes sized around 250 nm, correlating with 
the sizes measured using DLS. 
3.4.3 Transfection efficiency of liposomes encapsulating pLL and bPEI 
condensed DNA  
For both pLL and bPEI condensed DNA, the PR_b functionalized stealth 
liposomes mediated better transfection than the non- targeted liposomes (Fig. 
13). However, when the targeted formulations are compared, the bPEI 
condensed system performed over an order of magnitude better in terms of 
transfection efficiency than the pLL condensed system. These results are 
consistent with previous studies reported in the literature showing that bPEI 
condensed DNA performs better than the pLL counterpart in different gene 
delivery systems.161–163,193 Unencapsulated DNA particles condensed with either 
pLL or bPEI were both ineffective at transfecting DLD-1 cells to any appreciable 
extent under the same conditions. At the same time non-targeted stealth 
liposomes encapsulating the same amount of DNA failed to give a noticeable 
level of transfection. These results demonstrate the stealth properties of these 
non- targeted liposomes, as the PEG brush layer is preventing these liposomes 
from interacting with and delivering their payload to cells. 
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Figure 13. Transfection efficiency of liposome encapsulated and unencapsulated 
DNA condensed with bPEI or pLL 
100 ng of DNA was delivered in different formulations to DLD-1 cells and incubated for 40 
h at 37 ºC, after which luminescence was measured. The values represent mean  ± 
standard error of two separate experiments (n=2), each done in replicates of six. 
 
 
As our results show, transfection is successful when the PR_b targeting peptide 
is included on the stealth liposomes.  
3.4.4 Effect of PR_b concentration on transfection  
Having demonstrated the necessity of the PR_b peptide on our gene delivery 
vehicle, the PR_b concentration was optimized on stealth liposomes. As the 
concentration of the ligand is increased, an increase in the expression of 
luciferase in DLD-1 cells was observed (Fig. 14). At an average concentration of 
1.5 mol% PR_b the transfection level of the targeted liposomes was only slightly 
higher than the non-targeted system. However at an average of 3 mol% a 
substantial difference was observed between transfection levels of non-targeted 
and targeted liposomes. 
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Figure 14. Effect of PR_b concentration on transfection efficiency. 
100 ng of bPEI condensed DNA encapsulated in different stealth liposome formulations 
was delivered to DLD-1 cells and incubated for 40 h at 37 ºC, followed by luminescence 
measurement. The values represent mean ± standard error of three separate liposomal 
experiments (n =3), each done in replicates of six. Students t-test statistical analysis was 
performed and the statistical significance notated for the bracketed data. * indicates 
p<0.005; † indicates p>0.5 and no statistical significance. 
 
Average concentrations of 4 and 5 mol% PR_b showed similar levels of 
transfection with no statistical difference between them, and both substantially 
higher than non-targeted liposomes. This increasing trend was maintained up to 
about 9 mol% PR_b, the highest concentration that we investigated. A similar 
trend with the PR_b concentration was seen in a previous study by our group 
delivering liposomes encapsulating a fluorescent dye to colorectal cancer cells,19 
where conventional liposomes functionalized with PR_b between 0.7 and 3.5 
mol% and PEGylated liposomes with PR_b between 1.1 and 2.6 mol% were 
tested. One hypothesis that can explain the effect of ligand concentration is the 
requirement of a certain minimum number of receptor-ligand interactions for the 
delivery vehicle to remain at the cell surface long enough to be internalized 
through a receptor mediated pathway. This requirement further adds to the 
specificity of the delivery vehicle. Healthy tissues, which may have a lower 
number of integrin receptors, may not achieve the required number of integrin-
	   45	  
ligand interactions and therefore may not be transfected. Although the highest 
levels of transfection were obtained with 9 mol% PR_b, sufficiently high 
transfection levels were also observed at 4 and 5 mol % PR_b. Thus, for 
subsequent in vitro and in vivo work, liposomes were prepared with an average 
of 4 or 5 mol% PR_b concentration. We did not examine peptide concentrations 
higher than 9 mol%, as previous work in our group demonstrated that Langmuir-
Blodgett bilayers of peptide amphiphiles mixed with PEGylated lipids remained 
well-mixed at molar concentrations less than 10 mol% and higher than 35 mol%, 
while between 10 and 35 mol% the peptide amphiphiles phase separated.194  
3.4.5 Demonstrating specificity of targeting                
The GRGDSP peptide is a known binding ligand for integrins, including the α5β1 
integrin. Blocking the integrin sites with an excess of free GRGDSP peptide 
would theoretically prevent the PR_b peptide from binding and thus hinder 
transfection. A 1000-fold excess of GRGDSP over the number of PR_b ligands 
on liposomes was used in these experiments, an average of 4 µg peptide per 
well in a 96 well plate. Additional GRGDSP was added every 8 h to maintain an 
excess of blocking peptide, as this schedule proved to be more effective at 
blocking integrin binding compared to a large initial dose.  Fig. 15A shows that 
PR_b liposomes transfected unblocked cells at a level over an order of 
magnitude higher than the blocked liposomes. This experiment demonstrates the 
necessity of the integrin-PR_b interaction for successful transfection using the 
PR_b functionalized liposomal gene delivery vehicle. The results of these 
experiments are in agreement with our previously reported work where blocking 
experiments with peptides and antibodies demonstrated that PR_b is a specific 
ligand for the α5β1 integrin,19,186 with a dissociation constant of 76.3 ± 6.3 nM.195 
To further investigate the specificity of the PR_b sequence for α5β1 integrin, a 
scrambled PR_b sequence (ScrPR_b) was designed as a negative control. 
Fig.15B shows that in DLD-1 cells bPEI-DNA encapsulated in ScrPR_b 
functionalized stealth liposomes mediated minimal luciferase  
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Figure 15. Demonstrating specifity of gene delivery 
A) Delivery of bPEI condensed DNA encapsulated in PR_b functionalized PEGylated 
liposomes to either unblocked DLD-1 cells or DLD-1 cells with their surface integrins 
blocked by GRGDSP peptides free in solution. Cells were incubated with 100 ng of DNA 
loaded stealth liposomes functionalized with 5 mol% PEG2000 and 5.3, 4 and 4 mol % 
PR_b (for the three liposomal formulations tested) for 40 h at 37 ºC after which the 
luminescence was quantified. B) Delivery of bPEI condensed DNA encapsulated in PR_b 
functionalized or Scrambled PR_b functionalized PEGylated liposomes to either 
unblocked DLD-1 cells or DLD-1 cells with their surface integrins blocked by PR_b 
peptides free in solution. Cells were incubated with 100 ng of DNA loaded stealth 
liposomes functionalized with 5 mol% PEG2000 and 4.8, 6.1 and 5.9 mol% PR_b or 6.4, 
5.4 and 5.9 mol% ScrPR_b for 40 h at 37 ⁰C after which the luminescence was 
quantified. The values represent mean ± standard error of three separate liposomal 
experiments (n =3), each done in replicates of six. Students t-test statistical analysis was 
performed and the statistical significance notated for the bracketed data. * indicates 
p<0.001.  
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Figure 16. Effect of transfection agents on cell viability.  
100% cell viability is representative of untreated cells.  DLD-1 cells were treated with 
PR_b (3.9, 4.1 and 6.1 mol%) functionalized stealth liposomes (5 mol% PEG2000) 
encapsulating bPEI-DNA or free bPEI-DNA followed by WST-1 treatment and 
absorbance measurement. The values represent mean ± standard error of three separate 
liposomal experiments (n =3), each done in replicates of six. 
 
expression when compared to PR_b functionalized stealth liposomes. 
Furthermore, blocking with the free PR_b peptide inhibited the interaction of 
PR_b functionalized liposomes with DLD-1 cells almost completely. These 
results, taken together with the GRGDSP-blocking experiments shown in Fig. 
15A, demonstrate the need for a specific integrin-PR_b interaction for efficient 
transfection. 
3.4.6 Cytotoxicity of transfection agents 
Transfection subjects cells to high stress levels that scale with the amount of 
genetic material being introduced into the cells.123 However, at the concentrations 
of DNA used in our experiments the PR_b targeted system is able to increase 
transfection efficiency without adversely affecting cell viability (Fig. 16). Previous 
studies have shown that the electrostatic method of intracellular DNA uptake 
maybe detrimental to cell viability.125 For bPEI, the stronger the electrostatic 
attraction between the delivery vehicle and the cells, the higher the transfection 
level at the expense of cell viability. The non-electrostatic uptake of  
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Figure 17. Bioluminescence from luciferase expression after in vivo administration  
700 ng of bPEI-condensed DNA encapsulated in different stealth liposome formulations 
were injected into mice via tail vein. 24 h after liposome injection expression of luciferase 
was visualized by bioluminescence imaging. Total relative optical intensity (ROI) is shown 
for each image as measured in photons/second/cm2 by the Xenogen IVIS Imaging 
System A) Non-targeted stealth liposomes, with 5 mol% PEG2000, delivered to CT26 
tumor bearing mice. B) 3.3 mol% PR_b functionalized stealth liposomes (5 mol% 
PEG2000) delivered to healthy mice. C) 3.3 mol% PR_b and 5 mol% PEG2000 targeted 
stealth liposomes delivered to CT26 tumor bearing mice. 
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PR_b functionalized liposomes could be a reason for high cell viability concurrent 
with high transfection.  
3.4.7 In vivo gene delivery 
Non-targeted stealth liposomes injected into tumor-bearing mice (Fig. 17A) and 
PR_b functionalized stealth liposomes injected into healthy mice (Fig. 17B) 
showed minimal to no bioluminescent signal after one day. Considering that non-
specific delivery to healthy organs continues to be a drawback for in vivo delivery 
vehicles,196 the lack of luciferase expression in the healthy mice may indicate 
minimum levels of gene delivery to healthy tissues using the PR_b functionalized 
stealth liposomes. When these liposomes were administered to tumor-bearing 
mice, luciferase expression was seen preferentially in the region of the tumor, 
i.e., the liver (Fig. 17C). This metastatic tumor model has been designed to 
localize the tumor in the liver, and Fig. 18 (A, B) is an ex vivo image of the 
dissected abdomen from mouse 12 in Fig. 17C, clearly showing the presence of 
luciferase expressing tumor localized in the liver.  
Our preliminary results are in contrast to previous studies targeting the integrins 
in vivo in which significant non-specific uptake in the liver was reported.9,11,13,197 
Ex vivo images of the liver are shown in Fig. 18C, and a closer inspection shows 
bioluminescence in the liver tissue originating from the tumor nodules, and 
minimal signal from the surrounding healthy liver tissue (Fig. 18D). The essence 
of targeted therapy is in the specificity of delivery - in the ability to differentiate 
between healthy organs and the diseased site. Figs. 17 and 18 show that PR_b 
functionalized stealth liposomes may have the potential to differentiate not only 
between healthy organs and tumor bearing organs, but also between tumor 
tissue and healthy tissue within the same organ. Our preliminary in vivo studies 
show that the PR_b functionalized stealth liposome warrants further investigation 
as an in vivo delivery vehicle for therapeutic payloads.  
In addition, most in vivo studies report administration of anywhere from 5 to 50 
µg of DNA per mouse.156,187,198,199 A high dose combined with poor specificity can 
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Figure 18. Ex vivo bioluminescence from luciferase expression  
Images taken from abdominal dissection of mouse 12 shown in Fig. 17 after experimental 
endpoint. Total relative optical intensity (ROI) as measured in photons/second/cm2 by the 
Xenogen IVIS Imaging Sytem is shown for each image. Lateral dissection showing tumor 
load on liver (A) with superimposed bioluminescence (B). Excised liver showing white 
tumor nodules (C) with superimposed bioluminescence (D). 
 
result in significant undesirable accumulation of therapeutics in healthy tissues. In 
this paper we have demonstrated the in vitro specificity of the PR_b 
functionalized liposome, and shown in our in vivo work that we can potentially 
achieve gene expression specifically in the target site with less than 1 µg DNA 
injected per mouse. However, whether this expression level is enough to achieve 
a therapeutic effect still needs to be investigated. 
3.5 Conclusion 
We have designed and developed a gene delivery vehicle that encapsulates 
bPEI condensed DNA in PR_b functionalized stealth liposomes. The PR_b 
targeted vehicle is biocompatible, non-toxic, stable to aggregation, and 
specifically targets cells overexpressing α5β1 integrin with the potential to 
differentiate between healthy and diseased tissue within the same organ. Many 
diseased cells including cancers often overexpress α5β1 integrin, making the 
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PR_b functionalized stealth liposome a potentially effective therapeutic delivery 
agent that may specifically reach the diseased site while sparing healthy tissues.  
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Chapter 4. Transfection mechanisms of polyplexes, 
lipoplexes and stealth liposomes in α5β1 integrin 
bearing DLD-1 colorectal cancer cells 
4.1 Summary 
Receptor targeted, PEGylated transfection agents can improve stability and 
delivery specificity of current cationic lipid and polymer based non-viral gene 
delivery vehicles, but their mode of transfection is poorly understood. We 
therefore investigated the transfection mechanisms of 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP)/1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) lipoplexes, branched polyethylenimine (bPEI) 
polyplexes, and bPEI encapsulated in either PEGylated (stealth) non-targeted 
liposomes or PR_b peptide (targeted to α5β1 integrin) functionalized stealth 
liposomes in DLD-1 colorectal cancer cells in vitro with gene expression assays, 
flow cytometry and confocal microscopy. DOTAP/DOPE and PR_b functionalized 
stealth liposomes mediated higher gene expression compared to non-targeted 
stealth liposomes and bPEI. However DOTAP/DOPE was internalized slowly 
leading to lower levels of DNA uptake. In contrast, despite high internalization of 
bPEI polyplexes, gene expression levels were low as DNA was unable to escape 
from the endosomes. Non-targeted stealth liposomes also mediated low gene 
expression due to low amounts of DNA internalized and slow internalization 
kinetics. PR_b functionalized stealth liposomes struck an optimal balance 
amongst these transfection agents with efficient transfection arising from fast 
integrin mediated internalization kinetics, high amounts of DNA uptake and 
endosomal escape. We found α5β1 integrin to be a valuable target for gene 
delivery, and that the caveolar endocytic pathway may offer an advantage to 
receptor targeted PEGylated transfection agents in DLD-1 cells. 
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4.2 Introduction 
Gene delivery vectors face many challenges when administered in vivo.3,200 
These include survival in blood circulation when systemically administered, 
recognition of and uptake into target cells, and successful endosomal escape and 
nuclear localization. Delivery vectors need to navigate past each of these barriers 
before successful gene expression. Current gene delivery vectors can be broadly 
classified as viral or non-viral vectors.3,4 Although non-viral agents often have 
lower transfection efficiencies than viral vectors, they are safer, less 
immunogenic, more tunable and easier to build.5,6 These advantages make non-
viral vectors an attractive medium for gene delivery and much progress has been 
made in their development.3 However, many of the current non-viral transfection 
agents that mediate gene expression in vitro are still ineffective in vivo.30 For 
example, commonly used transfection agents based solely on cationic polymers 
like bPEI117,118 and cationic lipid mixtures like DOTAP/DOPE119 are unstable 
(prone to aggregation) under in vivo conditions and often toxic to healthy 
cells.123,124 Surface modification with a polyethylene glycol (PEG) layer may be 
used to increase stability and lower non-specific toxicity, but it often reduces 
transfection efficiency by reducing internalization into cells and hampering 
endosomal release.127,128 To increase transfection mediated by PEGylated 
systems, targeting moieties can be included on the nanoparticles to encourage 
specific receptor mediated uptake.129,196 However, although incorporation of 
targeting ligands may be able to increase cell internalization, it does not 
necessarily mediate the same level of transfection as the non-PEGylated, non-
targeted delivery systems.201 In order to design transfection agents with high 
transfection efficiencies without sacrificing stability and delivery specificity, it is 
necessary to better understand their mode of action in vitro.  
Currently, the transfection mechanism of targeted PEGylated systems and how it 
differs from those of conventional cationic polymer or lipid based transfection 
agents is poorly understood. Researchers investigating transfection mechanisms 
of these agents often disagree and provide no consensus on the mode of their 
transfection.3,22,23 It is apparent that different transfection agents are effective in 
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different cell lines, but reasons behind the differential activity are not clear. One 
of the factors that may play an important role in determining transfection 
efficiency is the internalization pathway utilized by these transfection agents.24 
Clathrin mediated endocytosis, caveolar mediated endocytosis and 
macropinocytosis are major pathways that have been implicated so far in the 
cellular uptake of transfection agents; however, it is not clear if certain pathways 
are more effective than others.23,25,26 More work is therefore needed to 
characterize these non-viral nanoparticles used for gene delivery. 
In this study, the transfection mechanisms of several different transfection agents 
were investigated, with a focus on understanding targeted PEGylated systems 
compared to commonly used polyplexes and lipoplexes. Specifically, we studied 
how DOTAP/DOPE based lipoplexes, bPEI based polyplexes, stealth liposomes 
encapsulating bPEI condensed DNA and PR_b peptide functionalized stealth 
liposomes encapsulating bPEI condensed DNA202 transfect DLD-1 human 
colorectal cancer cells. PR_b functionalized stealth liposomes is a transfection 
agent developed in our group, and was shown to have efficient transfection 
properties in vitro and in vivo.202 The targeting ligand PR_b (with amino acid 
sequence KSSPHSRNSGSGSGSGSGRGDSP) is a fibronectin mimetic peptide 
designed to specifically bind to α5β1 integrin with a binding affinity of 76.3 ± 6.3 
nM 17,195 and has been successfully used to functionalize nanoparticles for a 
variety of targeted delivery applications.20,21,185,203,204 PR_b functionalized 
nanoparticles were shown to outperform nanoparticles functionalized with other 
RGD based sequences at delivering payloads to α5β1 integrin receptor bearing 
cells, and could also differentiate between cells that expressed different levels of 
the α5β1 integrin receptor.186 α5β1 integrin is a well-known cancer marker that is 
overexpressed in cancer tissue and cancer vasculature14,15 thereby making it a 
good target for cancer-specific gene delivery. Previous experiments showed that 
PR_b functionalized stealth liposomes targeted to α5β1 integrin bearing cells can 
outperform non-targeted stealth liposomes as well as bPEI polyplexes.202 One of 
our goals here is to identify reasons behind differences in transfection mediated 
by different agents. In addition, we also aim to investigate barriers to gene 
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expression faced by these different transfection agents and suggest potential 
design parameters to overcome them.  
Flow cytometry and confocal microscopy were used to identify the transfection 
mechanisms of DOTAP/DOPE lipoplexes, bPEI polyplexes, stealth liposomes 
and PR_b functionalized stealth liposomes. Carefully selected chemical inhibitors 
for clathrin mediated endocytosis, caveolar mediated endocytosis and 
macropinocytosis, previously shown to successfully inhibit their respective 
routes,27,28 were used to identify the major internalization routes preferred by 
each of the transfection agents. At the end, a combination of observations from 
the transfection and DNA uptake levels, internalization rate kinetics, intracellular 
colocalization and inhibition of endocytosis aided in understanding the mode of 
transfection of the different agents investigated. DOTAP/DOPE and PR_b 
functionalized stealth liposomes proved to be most efficient at gene expression. 
Non-targeted stealth liposomes suffered from poor uptake and slow 
internalization kinetics. Contrary to some previous studies,117,118 bPEI failed to 
transfect due to its inability to escape acidic intracellular organelles. Our results 
implicate a combination of a caveolar and macropinocytosis mediated endocytic 
pathways as the uptake routes that may lead to successful gene expression 
following transfection of DLD-1 cells by targeting the α5β1 integrin with PR_b 
peptide functionalized delivery nanoparticles. Overall, PR_b functionalized stealth 
liposomes, with high DNA uptake, fast integrin-mediated internalization and 
endosomal escape, demonstrated efficient gene expression in DLD-1 cells.  
4.3 Materials and Methods 
4.3.1 Formulation and characterization of transfection agents  
25 kDa branched polyethylenimine (bPEI) (Sigma Aldrich, St Louis, MO) 
dissolved in distilled water was added to a solution of plasmid DNA in 10 mM 
Tris-HCl buffer for an amine to phosphate ratio (N/P) of 8. This ratio was deemed 
to be in the optimal charge ratio range as discussed previously, resulting in 
particles 63.5±0.6 nm in diameter and a zeta potential of 44.3±2.18 mV.202 The 
mixture was rapidly pipetted, followed by vortexing at the slowest speed setting 
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for 5 min. The condensed DNA was then incubated at room temperature for 30 
min before use.  
1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamine (DOPE) lipids (Avanti Polar Lipids Inc, 
Alabaster, AL) were mixed together at an equivalent molar ratio, and made into 
100 nm liposomes using a thin film lipid water hydration process190 followed by 
extrusion through 100 nm polycarbonate membranes in a Liposofast hand held 
extruder (Avestin, Ontario, CA). N/P ratios for lipid-DNA mixtures were calculated 
as previously described.188  The DOTAP/DOPE liposomes were added to a 
plasmid DNA solution in 10 mM Tris-HCl and rapidly mixed by pipetting followed 
by vortexing at the slowest speed for 5 min. DNA was condensed at different N/P 
ratios to obtain particles that best matched the bPEI condensed DNA particles for 
charge (Fig. 19), and N/P of 6 proved optimal. The DOTAP/DOPE condensed 
DNA particles were incubated at room temperature for 30 min before use.  
Lipids used in the formation of liposomes, 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-3 phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (ammonium salt) (DPPE-PEG2000) and 
cholesterol, were purchased from Avanti Polar Lipids, Inc (Alabaster, AL). The 
PR_b peptide (KSSPHSRNSGSGSGSGSGRGDSP) was purchased from the 
University of Minnesota Genomics Center (UMGC) and formed into an 
amphiphile by attaching a dialkyl C16 lipid tail to the amine-terminus of the peptide 
headgroup as previously described.17 PR_b functionalized stealth liposomes and 
non-targeted stealth liposomes were made using a thin film lipid hydration 
method, which was previously shown to be the best liposome formulation method 
for the encapsulation of condensed DNA.205 Briefly, a mixture of lipids containing 
x mol % PR_b peptide-amphiphiles, 5 mol % DPPE-PEG2000, (60-x) mol % 
DPPC and 35 mol % cholesterol were deposited in a 50 ml round bottom flask 
and dried under a stream of argon (x = 0 for non-targeted stealth liposomes and 
5 for PR_b functionalized stealth liposomes). Plasmid DNA was labeled with 
Label IT cy5 fluorescent probe (Mirus, Madison, WI) according to the 
manufacturer’s instructions. bPEI condensed DNA (including 5% or 25% cy5 
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labeled DNA) at an N/P ratio of 8 was then used to hydrate the lipid film for 2 h in 
a water bath held at 45 ᵒC. Following this incubation, the hydrated liposomes 
were extruded through 400 nm polycarbonate membranes in a hand held 
Liposofast extruder (Avestin, Ontario, Canada) to obtain non-targeted stealth 
liposomes of 204 ± 6 nm and PR_b functionalized stealth liposomes 279 ± 51 nm 
in diameter. Liposomes were then dialyzed against water for 24 h in a 1000 kDa 
MWCO dialysis membrane (Spectrum labs, Rancho Dominguez, CA) with 
frequent water changes.  
For all transfection agents, particle sizes and zeta potentials were measured with 
dynamic light scattering (DLS) on the ZetaPALS zeta potential analyzer 
(Brookhaven instruments, Holtsville, NY). For PR_b functionalized stealth 
liposomes, the lipid content was measured using a phosphorus assay191 
(reagents purchased from Sigma Aldrich). The PR_b peptide concentration was 
measured using a bicinchoninic acid (BCA) protein assay (Thermo Scientific, 
Waltham, MA) according to the manufacturer’s instructions, and reported as a 
mol % of total lipids. The DNA concentration in the liposomes were measured 
using a cy5 fluorescence standard as described previously.202,205 
4.3.2 Luciferase DNA transfection and luminescence measurement 
DLD-1 human colorectal cancer cells (ATCC, Manassas, VA), grown to 70-80% 
confluence in T-75 flasks in Dulbecco’s Modified Eagle Medium (DMEM) 
(Invitrogen supply center, University of Minnesota) supplemented with 10% fetal 
bovine serum and 10% of a 10,000 units/ml penicillin – 10 mg/ml  streptomycin 
solution (Sigma Aldrich, St Louis, MO), were subcultured into white 96 well plates 
at 5,000 cells/well in 100 µl of medium. Medium was replenished the next day 
and 100 ng of 5% cy5 labeled pT2/Cal187 DNA (a Firefly luciferase expression 
plasmid, gift from Prof. McIvor, University of Minnesota) were delivered per well 
with the different transfection agents. The transfection agents were incubated 
with the cells for 48 h at 37 °C and 5% CO2. The non-targeted stealth and PR_b 
functionalized stealth liposomes used here contained 5% cy5 labeled condensed 
DNA for quantification of DNA encapsulation. Following incubation, cells were 
washed once with 200 µl phosphate buffered saline (PBS) and the Luciferase 
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reporter assay kit (Promega, Madison, WI) used according to the manufacturer’s 
protocol. A luminescence plate reader (Biotek, Winooski, VT) was used to 
measure luminescence resulting from luciferase expression.  
4.3.3 Evaluation of transfection efficiency with flow cytometry 
DLD-1 cells were subcultured in clear 12 well plates at 100,000 cells/well in 1 ml 
of medium. Medium was replenished the next day and 1 µg of 5% cy5 labeled 
pmaxGFP plasmid DNA (gift from Prof. Hu, University of Minnesota) was 
delivered per well with the different transfection agents for 24 h at 37 °C and 5% 
CO2. Non-targeted stealth liposomes and PR_b functionalized stealth liposomes 
used here contained 5 % cy5 labeled DNA. Cells were washed once with 1 ml 
PBS, medium was replenished and incubation continued for 24 h more. Cells 
were then harvested with TrypleE Express cell dissociation reagent (Invitrogen 
supply center, University of Minnesota), pelleted by centrifugation at 250 g for 5 
min, resuspended in PBS and analyzed on a FACSCalibur flow cytometer 
(Masonic cancer center, University of Minnesota). Transfection efficiency is 
reported as the percentage of cells expressing GFP compared to the 
untransfected cells (% positive difference reported by the FCS express software). 
4.3.4 Evaluation of DNA uptake and internalization kinetics with flow 
cytometry 
DLD-1 cells were subcultured in clear 12 well plates at 100,000 cells/well in 1 ml 
of medium. Medium was replenished the next day and 1 µg of 25% cy5 labeled 
pT2/Cal DNA was delivered per well with the different transfection agents for 24 h 
at 37 °C and 5% CO2. Cells were washed once with 1 ml cold PBS and harvested 
with TrypleE Express cell dissociation agent (Invitrogen supply center, University 
of Minnesota), pelleted by centrifugation at 250 g for 5 min. In order to remove 
any DNA still attached to the cell surface, cells were treated with 100 μl Trypsin 
and 0.5 ml of 0.5 mg/ml heparin sulfate solution (Sigma Aldrich, St Louis, MO) for 
5 min. Following another PBS wash and recentrifugation, cells were resuspended 
in 1 ml cold PBS and analyzed using a FACSCalibur flow cytometer (Masonic 
cancer center, University of Minnesota). DNA uptake efficiency is reported as the 
percentage of cells with internalized DNA compared to untransfected cells (% 
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positive difference reported by the FCS express software). To measure 
internalization kinetics similar techniques were followed, but transfection agents 
were allowed to incubate with cells for a range of different times: 0.5, 1, 2, 6, 12 
and 24 h.  
4.3.5 Confocal microscopy 
DLD-1 cells were subcultured on 20 mm fibronectin coated cover slips (Neuvitro, 
El Monte, CA) in a clear 12 well plate at 100,000 cells/well in 1 ml of medium. 
The following day, the fibronectin coverslips were transferred to a new well with 
fresh medium, and BacMam 2.0 Cell light early endosome GFP label  (Life 
technologies, Grand Island, NY) added to the cells at 15 µl/well along with 5 mM 
sodium butyrate (Sigma Aldrich, St Louis, MO). 24 h later, 25% cy5 labeled DNA 
was transfected into cells using different transfection agents and incubated for 24 
h at 37 °C and 5% CO2. The wells were washed the following day with 1ml PBS 
and incubation continued for a further 24 h. 2 h before experimental endpoint, 15 
µl of a 20 µM solution of Lysotracker Red DND-99 (Life technologies, Grand 
Island, NY) was added to cells in 1ml of medium for a final concentration of 300 
nM. Cells were then washed in PBS and fixed by treating with freshly made 4 
(w/v) % paraformaldehyde (Sigma Aldrich, St Louis, MO). Nuclei were labeled by 
adding 1 μl of Hoescht 33432 (Life Technologies, Grand Island, NY) in 1ml of 
PBS and incubating for 10 min at 37 °C and 5% CO2. Fibronectin coverslips were 
then washed with PBS and mounted with Prolong gold antifade reagent 
(Invitrogen, University of Minnesota) on microscope slides and visualized with an 
Olympus upright confocal microscope (University imaging center, University of 
Minnesota). . 
4.3.6 Cell viability after treatment with endocytic inhibitors 
DLD-1 cells were subcultured in a clear 96 well plate at 5000 cells/well in 100 μl 
of medium. Medium was replenished the next day, and cells were treated with 5 
μg/ml filipin III, 10 μg/ml chlorpromazine or 2 μM rottlerin at 37 °C and 5% CO2.  
All inhibitors were purchased from Sigma Aldrich (St Louis, MO). 30 min later, 10 
μl WST-1 reagent (Promega, Madison, WI) was added per well, and cell viability  
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Figure 19. Characterization of DOTAP/DOPE condensed DNA.  
A) Dynamic light scattering size measurement and B) corresponding zeta potential 
measurements for condensed pT2/Cal DNA particles at different amine (N) to phosphate 
(P) ratios. Data are presented as the mean ± standard error of three independent 
experiments (n=3), done in triplicate. 
 
measured according to the manufacturer’s protocol after a further 1h incubation 
at 37 °C and 5% CO2. 
4.3.7 Inhibition of endocytosis 
DLD-1 cells were subcultured in a clear 6 well plate at 250,000 cells/well in 1ml of 
medium. Medium was replenished the next day and cells were incubated with 5 
μg/ml filipin III, 10 μg/ml chlorpromazine or 2 μM rottlerin for 30 min at 37 °C and 
5 % CO2. All inhibitors were purchased from Sigma Aldrich (St Louis, MO). The 
concentrations of inhibitors used here are similar to levels previously shown to be 
effective (Section 2.3.4), and was verified for minimal cytotoxicity. Cells were  
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Figure 20. Comparison of luminescence from luciferase expression following 
transfection with different transfection agents.  
DLD-1 cells were transfected with 100 ng of pT2/Cal plasmid DNA delivered using 
DOTAP/DOPE, bPEI, non-targeted stealth liposomes (0% PR_b) or 5 mol% PR_b 
functionalized stealth liposomes for 48 h followed by luminescence measurement. Data 
are presented as mean ± standard error of four independent experiments (n=4) done in 
triplicate. Student's t-test statistical analysis was performed, * indicates p<0.01 and ** 
p<0.005. If no symbol is displayed there is no statistical significance for that pair. 
 
then incubated with 1 μg 25% cy5 labeled DNA/well delivered using different 
transfection agents for 1 h more under the same conditions. Cells were washed 
once with 1ml PBS and subsequent preparation and analyses were carried out 
using FACScalibur flow cytometer (Masonic cancer center, University of 
Minnesota) as described earlier for measuring DNA uptake (Section 4.3.4). 
4.4 Results  
4.4.1 Luciferase transfection in DLD-1 cells 
We first investigated the ability of DOTAP/DOPE, bPEI, non-targeted stealth 
liposomes or PR_b functionalized stealth liposomes to transfect DLD-1 human 
colorectal cancer cells with a luciferase expressing plasmid pT2/Cal (Fig. 20).187 
Results show that PR_b functionalized stealth liposomes outperformed non-
targeted stealth liposomes, demonstrating the need of the PR_b ligand for 
successful transfection using stealth liposomes. Also, PR_b functionalized stealth 
liposomes performed as well as DOTAP/DOPE lipoplexes in transfecting DLD-1 
cells. DOTAP/DOPE, given its structural and functional similarity to 
Lipofectamine, 2,3-dioleyloxy-N-[2-(sperminecarboxamido)ethyl]-N,N-dimethyl-1-
propanaminium/1,2-dioleoyl-sn-glycero-3-phosphoethanolamine  
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Figure 21. A) GFP expression levels and B) transfection efficiency following 
transfection with different agents.  
DLD-1 colorectal cancer cells were transfected with 1 μg pmaxGFP DNA using 
DOTAP/DOPE, bPEI, non-targeted stealth liposomes (0% PR_b) or 5.8 mol% PR_b 
functionalized stealth liposomes for 24 h at 37 °C and 5% CO2. GFP expression was 
quantified with flow cytometry after a further 24 h incubation. Transfection efficiency is 
reported as the percentage of cells expressing GFP compared to untransfected cells. 
Data are presented as mean ± standard error from four independent experiments (n=4) 
done in triplicate. Student's t-test was performed and bracketed data are statistically 
significant where * indicates p<0.05 and ** p<0.01.  
 
(DOSPA/DOPE), is one of the gold standards of in vitro non-viral transfection 
agents. Therefore, these results show that PR_b functionalized stealth liposomes 
possess efficient transfection properties. Fig. 20 also demonstrates that 
DOTAP/DOPE mediates better transfection than bPEI. This is not surprising, as 
there are several instances where cationic lipid based transfection agents have 
been shown to outperform cationic polymer based system.23,206 These results 
demonstrated the improvement in transfection of the bPEI after incorporating the 
bPEI polyplexes in a targeted delivery system such as the PR_b functionalized  
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Figure 22. A) DNA internalization and B) percentage of cells with internalized DNA 
after transfection with different agents 
DLD-1 colorectal cancer cells were transfected with 1 μg of 25% cy5 labeled pT2/Cal 
DNA using DOTAP/DOPE, bPEI, non-targeted stealth liposomes (0% PR_b) or 4.7 mol% 
PR_b functionalized stealth liposomes for 24 h at 37 °C and 5% CO2. Cells were washed 
and the amount of DNA internalized was quantified using flow cytometry. Percentage of 
cells with internalized DNA is reported relative to untransfected cells. Data are presented 
as mean ± standard error from four independent experiments (n=4) done in triplicate. 
Student's t-test was performed and bracketed data are statistically significant where * 
indicates p<0.05 and ** p<0.01. 
 
stealth liposomes. Next, we investigated the potential reasons behind the 
differences in gene expression mediated by these agents. 
4.4.2 Flow cytometric analysis of transfection and DNA uptake 
Flow cytometry was used to further investigate the transfection mechanisms of 
DOTAP/DOPE, bPEI, non-targeted stealth liposomes and PR_b functionalized 
stealth liposomes and to help understand the trends reported in Fig. 20. A green  
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Table 1 Summary and further analysis of data from Fig. 21 and Fig. 22.  
Abbreviations used - TFL : Transfection level (Figure 2A); TFE : Transfection efficiency 
(Figure 2B); UPL : Uptake level (Figure 3A); UPE : Uptake efficiency (Figure 
3B).TFL/TFE represents amount of protein expressed per cell; UPL/UPE represents 
amount of DNA internalized per cell; TFL/UPL represents amount of protein expression 
per amount of DNA internalized. 
 
fluorescent protein (GFP) expression plasmid, pmaxGFP, was used to transfect 
DLD-1 cells and GFP fluorescence was measured using flow cytometry (Fig. 21). 
Fig. 21A shows similar trends to the luciferase expression experiment, with 
DOTAP/DOPE and PR_b functionalized stealth liposomes both outperforming 
bPEI and non-targeted stealth liposomes. In addition, under these experimental 
conditions, PR_b functionalized stealth liposomes and DOTAP/DOPE transfected 
on average 36.4% and 38.6% of DLD-1 cells respectively, while bPEI and non-
targeted stealth liposomes trailed behind transfecting 5% and 9% of DLD-1 cells 
(Fig. 21B).  
To investigate whether the difference in transfection arose from a difference in 
DNA uptake, flow cytometry was used to measure cy5-labeled DNA uptake in 
DLD-1 cells after transfection with DOTAP/DOPE, bPEI, non-targeted stealth 
liposomes or PR_b functionalized stealth liposomes. Surprisingly, Fig. 22A shows 
that bPEI mediated better DNA uptake than any of the other transfection agents. 
Also, under these experimental conditions, all the transfection agents were able 
to internalize into most of the cells (Fig. 22B). Table 1 summarizes data from 
Figs. 21 and 22. Ratios of the different parameters measured were taken to 
represent various physical phenomena. For example, the level of transfection 
(Fig. 21A) divided by transfection efficiency (Fig. 21B) (TFL/TFE) represents total 
amount of protein produced per cell transfected. DOTAP/DOPE produced the 
highest amount of protein per cell, closely followed by PR_b functionalized 
liposomes, while bPEI and non-targeted stealth liposomes mediated protein 
production that was barely detectable. Given the similar DNA uptake efficiencies 
	  
TFL	   TFE	   UPL	   UPE	   TFL/TFE	   UPL/UPE	   TFL/UPL	  
DOTAP/DOPE	   3.03	   38.6	   128.0	   97.5	   0.0785	   1.31	   0.0237	  
PEI	   0.12	   5.1	   222.7	   99.1	   0.0236	   2.25	   0.0005	  
Stealth	  liposomes	   0.20	   9.3	   161.8	   97.5	   0.0216	   1.66	   0.0012	  
PR_b	  stealth	  liposomes	   1.96	   36.4	   92.7	   98.7	   0.0539	   0.94	   0.0212	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(Fig. 22B) of the different agents, bPEI resulted in the highest amount of DNA 
uptake per cell that had internalized DNA (results from Fig. 22A/Fig. 22B: 
UPL/UPE). Although DOTAP/DOPE mediated lower DNA internalization (Fig. 
22A), its high level of transfection (Fig. 21A) resulted in the highest ratio of 
protein produced to DNA uptake (TFL/UPL). PR_b functionalized stealth 
liposomes had a TFL/UPL ratio (protein produced per DNA uptake) similar to that 
of DOTAP/DOPE and 42 fold that of bPEI. Clearly, the differences in transfection 
levels are not because of differences in DNA uptake. We hypothesize that they 
may instead arise due to differences in the intracellular fate of these transfection 
agents.  
4.4.3 Visualization of intracellular fate with confocal microscopy 
To understand the intracellular fate of the transfection agents, cy5 labeled DNA 
(shown in red) delivered using DOTAP/DOPE, bPEI, non-targeted stealth 
liposomes or PR_b functionalized stealth liposomes was visualized using 
confocal microscopy in cells with Hoescht stained nuclei (shown in gray), GFP 
stained early endosomes (shown in blue) and lysotracker red labeled late 
endosomes or lysosomes (shown in green) (Fig. 23). The images were taken at 
48 h after transfection, equivalent to when protein expression was measured in 
Figs. 20 and 21. For bPEI (Figs. 23C and 23D), the majority of the DNA (red) is 
seen in the late endosomes or lysosomes (green) as indicated by the yellow 
bodies. Thus, in DLD-1 cells, bPEI is not able to escape the endosomal pathway. 
This may explain why despite resulting in a large amount of internalized DNA 
(Fig. 22A) bPEI cannot mediate protein expression (Figs. 20 and 21A). 
In contrast, there is a large amount of free DNA (red) for cells transfected with 
DOTAP/DOPE (Figs. 23A and 23B). There are several instances where free DNA 
is seen in the cytoplasm and in the nucleus (Fig. 23B) and some of the free DNA 
also appears in ensembles, a phenomenon absent for all the other transfection 
agents tested. The presence of the free DNA shows that DOTAP/DOPE is able to 
successfully escape the endosomal pathway, which explains the higher 
transfection seen (Figs. 20 and 21A). Therefore, the endosomal escape of DNA  
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Figure 23. Intracellular distribution of internalized DNA after transfection with 
different agents.  
DLD-1 human colorectal cancer cells were transfected with 1 μg of 25% cy5 labeled 
pT2/Cal DNA delivered using (A, B) DOTAP/DOPE, (C, D) bPEI, (E, F) non-targeted 
stealth liposomes or (G, H) 4.7 mol% PR_b functionalized stealth liposomes for 24 h at 
37 °C and 5% CO2. Following a further 24 h incubation, cells were imaged using confocal 
microscopy. Cy5 DNA is shown in red. Early endosomes (blue) were labeled with Cell 
light early endosomes-GFP, acidic organelles (green) were labeled with the Lysotracker 
Red and nuclei (gray) were labeled with Hoescht dye (color was removed to aid in 
interpretation). The specific combination of colors was chosen to aid in visual recognition 
of colocalization. Images shown here are representative of three independent 
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experiments (n=3) with panels B, D, F and H at original magnification and A, C, E, G 
zoomed out. Scale bar is 20 μm. 
 
generated by DOTAP/DOPE through the hexagonal phase transition of its 
constituent lipids121 appears to be quite effective in DLD-1 cells.  
A small amount of the DNA delivered with non-targeted stealth liposomes was 
internalized, and much of it still remained relatively far from the nucleus once 
internalized (Figs. 23E and 23F). This indicates that the internalization or 
subsequent trafficking, or a combination of both, of the stealth liposomes may be 
a slower process compared to the other transfection agents. Also, DNA delivered 
with the non-targeted stealth liposomes appeared as punctuate dots much 
smaller than those associated with the other transfection agents. This may 
possibly be due to overall less DNA being internalized with stealth liposomes. 
PR_b functionalized liposomes resulted in a higher amount of free red DNA seen 
inside the cell, and even in the nucleus in certain cases (Figs. 23G and 23H) 
compared to bPEI (Figs. 23C and 23D). These observations support the 
successful transfection that is mediated by PR_b functionalized stealth liposomes 
compared to bPEI. Taken together, the fact that PR_b functionalized stealth 
liposomes that encapsulate bPEI condensed DNA can successfully transfect 
DLD-1 cells, and that DNA can be visualized outside acidic compartments and in 
the nucleus, point to a favorable internalization route taken by these liposomes 
that allowed DNA to escape endosomes and enter the nucleus. However, much 
of the DNA internalized still appears sequestered in acidic organelles, which may 
mean that only part of the liposomes is internalized in a route favorable for 
transfection.   
4.4.4 Internalization kinetics 
Amount of DNA internalized into DLD-1 cells was measured over time after 
transfection with various transfection agents (Fig. 24). At all time points, bPEI 
and PR_b functionalized stealth liposomes mediated higher DNA internalization  
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Figure 24. Kinetics of DNA internalization following transfection with different 
agents.  
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DLD-1 colorectal cancer cells were transfected with 1 μg 25% cy5 labeled DNA using 
DOTAP/DOPE (blue u), bPEI (green n), stealth liposomes (purple ) or 4.7 mol% PR_b 
functionalized stealth liposomes (red x) for different times at 37 °C and 5% CO2. Cells 
were washed and quantified using flow cytometry,  (A,B) Total amount of DNA 
internalized, and C) Percentage of cells with internalized DNA reported as the percentage 
positive difference between transfected and untransfected cells. B) shows calculation of 
internalization rate kinetics from first 6 h of (A). Linear trendlines, shown in black, were 
fitted to the data points in Excel. The relative uptake rate of DNA for DOTAP/DOPE, 
bPEI, non-targeted stealth liposomes (0% PR_b) and 4.7 mol% PR_b functionalized 
stealth liposomes are 4.8x-0.3, 8.8x-2.6, 5.2x-2.3 and 18.4x-8.5 respectively, where x is 
time in h. DOTAP/DOPE and non-targeted stealth liposomes closely overlap at all the 
data points. Data are presented as mean ± standard error from three independent 
experiments (n=3) each done in triplicate.  
 
compared to DOTAP/DOPE and stealth liposomes. PR_b functionalized stealth 
liposomes outperformed even bPEI at lower time points. However, at higher time 
points, 24h, the rate of uptake mediated by PR_b functionalized stealth 
liposomes was a little lower compared to bPEI (Fig. 24). This conforms to the 
higher amount of DNA uptake mediated by bPEI at 24 h seen in Fig. 22A. In 
contrast, the rate of uptake of DOTAP/DOPE and non-targeted stealth liposomes 
was maintained at a lower level throughout the duration of the experiment 
4.4.5 Inhibition of endocytic pathways 
To investigate whether different internalization routes was a potential reason for 
the heterogeneous behavior exhibited by the transfection agents, different 
endocytic pathways were blocked and the effect on DNA internalization was 
measured with flow cytometry (Fig. 25). We chemically inhibited three specific 
endocytic pathways previously implicated in the uptake of non-viral gene delivery 
vehicles: clathrin-mediated endocytosis, caveolae-mediated endocytosis and 
macropinocytosis. The concentrations of the different inhibitors used were on the 
same order of magnitude as used in previous experiments,28,134 and their effect 
on cell viability was measured using a WST-1 metabolic assay (Fig. 26). Inhibitor 
concentrations and treatment times that showed minimum effect on cell viability 
were used in these experiments. Filipin III, which primarily blocks caveolae-
mediated endocytosis, only affected the internalization of PR_b functionalized 
stealth liposomes decreasing it by 23.3 ± 3.6%. Chlorpromazine, which primarily 
blocks clathrin-mediated endocytosis, decreased DOTAP/DOPE and the non-
targeted stealth liposome mediated DNA internalization by 56.3 ± 3.8 % and 24.4  
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Figure 25. Effect of endocytic inhibitors on DNA internalization after transfection 
with different agents.  
DLD-1 colorectal cancer cells were pretreated with different inhibitors for 30 min and 
transfected with 1 μg of 25% cy5 labeled pT2/Cal DNA using DOTAP/DOPE, bPEI, non-
targeted stealth liposomes (0%) or 4.7 mol% PR_b functionalized stealth liposomes for 1 
h at 37 °C and 5% CO2. The different inhibitors used were filipin III (red n), for caveolar-
mediated endocytosis, chlorpromazine (gray n), which blocks clathrin-mediated 
endocytosis and rottlerin (black n) that inhibits macropinocytosis. Cells were washed and 
the amount of DNA internalized quantified using flow cytometry. Data are presented as 
mean ± standard error from three independent experiments (n=3) done in triplicate. 
Student's t-test was performed and symbols directly over bars represent significance 
compared to untreated samples: * p<0.005. 
 
± 5.2%, while minimally affecting the PR_b functionalized stealth liposomes and 
bPEI. Rottlerin, which primarily inhibits macropinocytosis, decreased DNA 
internalization of all the transfection agents but affected the non-targeted stealth 
liposomes and bPEI more strongly, reducing DNA internalization by 55.7 ± 6.7% 
and 39.4 ± 6.1 % respectively.  
4.5 Discussion 
Results from experimental investigations into the effect of blocking endocytosis 
pathways are often confounded by a variety of factors, and caution is advised in 
their interpretation.145,207 First of all, many chemical inhibitors are not specific to a 
single internalization pathway. Also, inhibiting certain endocytosis pathways can 
artificially upregulate other internalization routes that are not originally involved in 
transfection agent uptake. For these reasons, our inhibition experiments were  
	   71	  
 
Figure 26. Cell viability after treatment with endocytic inhibitors.  
DLD-1 cells were treated with 5 μg/ml filipin III, 10 μg/ml chlorpromazine or 2 μM rottlerin 
for 1.5 h at 37 °C and 5% CO2 and cell viability was measured using the WST-1 
metabolic assay. Data are shown as the mean ± standard error from three independent 
experiments (n=3) done in triplicate, and are presented as a percentage of viability of 
untreated cells. 
 
designed to observe effects at short times and in the process minimize cell 
adaptation and upregulation of secondary uptake pathways.145 The scope of 
these experiments was not to identify exact quantitative combinations of specific 
internalization pathways involved in the uptake of the different transfection 
agents, but to observe relative differences in the uptake of transfection agents 
after cells were treated with chemical inhibitors. Endocytic pathways can be 
classified as non-lipid raft mediated (clathrin mediated), mixed lipid mediated 
(phagocytosis and macropinocytosis), and lipid-raft mediated (caveolae, flotillin, 
Arf6, GRAF-1 and Rho-A mediated).24 Phagocytosis is involved in the uptake of 
particles > 0.5 μm in diameter,138 and was not investigated in this study as all our 
transfection agents were smaller in diameter at the time of transfection. Out of 
the rest, clathrin mediated, caveolae mediated and macropinocytosis have been 
previously implicated in the uptake of transfection agents;23,26,27 in accordance, 
our results showed these pathways played different roles in the uptake of the 
different transfection agents tested in DLD-1 cells. The rest of the lipid-raft 
mediated endocytic pathways have intertwined roles and as yet lack specific 
chemical inhibitors,150 and were not investigated in this study. 
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DOTAP/DOPE lipoplex mediated transfection was most successful after DNA 
internalization, leading to the highest protein production to DNA uptake ratio 
(Table 1). Lower amounts of DNA were internalized with DOTAP/DOPE (Fig. 
22A) and this was further corroborated by slow internalization kinetics measured 
by flow cytometry (Fig. 24). Inhibition of endocytosis pathway blocking implicated 
mostly clathrin-mediated endocytosis and some macropinocytosis as pathways 
involved in DOTAP/DOPE mediated DNA uptake (Fig. 25). Also, DOTAP/DOPE 
has been previously demonstrated to be unstable in serum conditions, making 
them unsuitable for in vivo gene delivery.119 In addition, DOTAP/DOPE lipoplexes 
mediate transfection in a non-specific manner, and is unable to differentiate 
between a specific set of target cells and off-target cells. In contrast, our previous 
studies have shown that PR_b functionalized nanoparticles can specifically 
transfect α5β1 integrin bearing cells.202 Fig. 20 shows that PR_b functionalized 
stealth liposomes can mediate the same level of transfection as DOTAP/DOPE in 
DLD-1 cells. In applications where gene expression is needed to be limited to 
cells bearing α5β1 integrin, in cancer treatment for example, PR_b functionalized 
stealth liposomes is the better choice for a transfection agent. 
bPEI has been previously shown to mediate transfection in cells, hypothesized to 
be facilitated by endosomal escape through a proton sponge effect.117 However, 
the efficacy of the proton sponge effect has been the subject of debate.164,208,209 
Previous studies have presented situations where bPEI polyplexes are unable to 
escape endosomes, and that further modifications are necessary to improve 
transfection efficiency.209,210 Our results demonstrate such a situation where bPEI 
polyplexes are stuck in organelles such as lysosomes as evident by their 
colocalization with the green organelles (Figs. 23C and 23D). Despite having 
better transfection properties compared to other polymers such as poly-L-
lysine,202 bPEI has a lot of room for improvement with regard to lysosomal 
escape in DLD-1 cells.  
Macropinocytosis has been suggested as an uptake route that can help increase 
transfection in CHO cells by amphiphilic transfection agents and in NIH3T3 cells 
by high density octaarginine modified liposomes.26,211 In our studies 
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macropinocytosis was found to be the primary pathway involved in the uptake of 
bPEI and non-targeted stealth liposomes (Fig. 25) but neither of these two 
transfection agents mediated a significant level of transfection in DLD-1 cells. 
Thus, macropinocytosis is not always conducive to gene transfection. These 
results can potentially be explained by the fact that different pathways are 
effective in the transfection of different cell lines.131 Also, escape from 
macropinosomes is an inefficient process.212 In accordance, non-targeted stealth 
liposomes and bPEI both appear as punctuate dots within the cells (Fig. 23).  In 
addition, our internalization kinetics experiment shows that the rate of uptake of 
bPEI condensed DNA is almost twice as much as that of the non-targeted stealth 
liposomes (Fig. 24B). That implies that either macropinocytosis is proceeding at 
different rates for these transfection agents, or that one of the other lipid-raft 
mediated endocytic pathways is working in conjugation with macropinocytosis for 
bPEI uptake. In addition, the higher electrostatic binding of bPEI polyplexes to 
the cell membrane may also contribute to fast internalization kinetics. Consistent 
with the slow rate of uptake, most of the DNA delivered with the non-targeted 
stealth liposomes was seen further away from the nucleus in small punctate dots 
(Figs. 23E and 23F). Despite the slower uptake rate and peripheral DNA, there is 
no significant colocalization of the non-targeted stealth liposomes with early 
endosomes. This conforms to the idea that most non-targeted stealth liposomes 
are taken up in macropinosomes, which initially do not possess the Rab5 early 
endosome marker but acquire it during subsequent maturation.213 Eventually 
macropinosomes merge with acidic lysosomal compartments.213,214  
Our results implicated macropinocytosis and caveolar mediated endocytosis in 
the uptake of DNA encapsulated in PR_b functionalized stealth liposomes 
targeted to α5β1 integrin (Fig. 25). PR_b functionalized stealth liposomes partly 
comprise of bPEI condensed DNA and stealth liposomes. The presence of the 
PR_b peptide can change the uptake route from predominantly 
macropinocytosis, as seen for bPEI and non-targeted stealth liposomes, to one 
with a stronger caveolar influence. While macropinocytosis is involved in DNA 
uptake, the results from bPEI and the non-targeted stealth liposomes transfection 
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suggest that this may not be an effective internalization route for gene expression 
in DLD-1 cells for certain transfection agents. Amongst all the transfection agents 
tested here, only PR_b functionalized stealth liposomes were internalized using 
caveolar pathway. In a previous study with polyplexes modified with the RGD 
peptide, which also binds integrins, it was shown that the targeted polyplexes 
internalized via a caveolar pathway.215 In fact, it has been suggested that the 
caveolar uptake is the only productive internalization route for some transfection 
agents.27 Caveolae mediated endocytosis may confer an advantage to 
internalized DNA. While caveosomes were initially thought to be non-acidic and 
non-digestive compartments,216 recent evidence suggests that these organelles 
slowly merge with late endosomes over time.217 This slower maturation process 
could potentially allow more time for internalized cargo to escape the endosomal 
pathway.25 Additionally, caveolae have previously been implicated in the uptake 
of β1 integrins.218 In accordance, our results show that targeting α5β1 integrin with 
the PR_b peptide functionalized stealth liposomes promotes cellular 
internalization mediated by caveolae.  
We show that different transfection agents appear to be facing different barriers 
to gene expression. DOTAP/DOPE mediates good transfection when 
internalized, but suffers from a low uptake rate. Non-targeted stealth liposomes 
have poor transfection efficiency in part due to slow internalization kinetics. As 
discussed in the introduction section, the in vivo stability of transfection agents 
are often improved by addition of a PEG layer on the particle surface, at the 
expense of transfection efficiency. Our results show that an effective balance can 
be struck by using targeted stealth liposomes. PR_b functionalized stealth 
liposomes mediate fast internalization and have high transfection efficiency. In 
contrast to all the other transfection agents tested here, PR_b functionalized 
stealth liposomes are the only system that can mediate transfection in a specific 
target group of cells – namely, those bearing the α5β1 integrin. The specificity of 
PR_b functionalized nanoparticles for the α5β1 integrin has been extensively 
demonstrated before.186,202 Unfortunately, bPEI, a key component in the design of 
the PR_b functionalized transfection agent, when used on its own failed to 
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efficiently escape endosomes in DLD-1 cells. PR_b functionalized stealth 
liposomes may therefore be improved further by encapsulating DNA condensed 
using a different cationic polymer with better endosomal release properties. 
Our results support the notion that there is not a single transfection agent that is 
effective in all situations.131 Also, transfection agents appear to not have a 
consistent mechanism of mediating gene expression across different cell lines. 
For example, bPEI, which has been claimed to be a stellar polymer based 
transfection agent in other cells,117,118 failed to promote appreciable gene 
expression in DLD-1 cells. Macropinocytosis, which has been claimed to offer an 
advantage to transfection agents,26 was ineffective at gene expression using 
bPEI and non-targeted stealth liposomes. Just as transfection agents themselves 
behave differently in different cell types, it appears that different endocytic 
pathways may have different fates also depending on the cell types.131 This is 
likely the reason why there is not a consensus on a correlation between 
transfection agents and their preferred internalization pathways, and also why 
there is a discord regarding which pathways offer the best advantage for 
mediating gene expression.  One way to generalize the behavior of transfection 
agents and predict outcomes of gene expression may be to study transfection 
mechanisms in a variety of different cell lines. Such information may enable us to 
decipher patterns in cell phenotypes and relate that to optimal transfection 
mechanisms within a group of cells.  
4.6 Conclusion 
We investigated the transfection mechanism of DOTAP/DOPE lipoplexes, bPEI 
polyplexes, non-targeted stealth liposomes and PR_b functionalized stealth 
liposomes in DLD-1 human colorectal cancer cells. The predominant form of 
endocytosis was clathrin mediated for DOTAP/DOPE, macropinocytosis for bPEI 
and non-targeted stealth liposomes and a combination of caveolar and 
macropinocytosis for PR_b targeted stealth liposomes. We discovered that bPEI 
may be ineffective in DLD-1 cells after internalization in macropinosomes and 
lysosomes. However, targeting to α5β1 integrin using PR_b functionalized 
nanoparticles, thereby switching the internalization route to caveolar or lipid raft 
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mediated pathways, can salvage gene expression. PR_b functionalized stealth 
liposomes are rapidly taken up with fast integrin-mediated internalization kinetics, 
mediate efficient transfection in DLD-1 cells, and can potentially benefit from 
additional advantages of the caveolar uptake pathway. 
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Chapter 5. Increasing cancer-specific gene 
expression by targeting overexpressed α5β1 
integrin and upregulated transcriptional activity of 
NF-κB 
 
5.1 Summary 
We developed a modular multi-functional non-viral gene delivery system by 
targeting the overexpressed cancer surface receptor α5β1 integrin and the 
upregulated transcriptional activity of the cancer resistance mediating 
transcription factor NF-κB, thereby introducing a new form of transcriptional 
targeting. NF-κB regulated therapy can improve specificity of gene expression in 
cancer tissue and also may offset NF-κB mediated cancer resistance. We 
delivered a luciferase gene under the control of an NF-κB responsive element 
(pNF-κB-Luc) encapsulated in a PR_b peptide functionalized stealth liposome 
that specifically targets the α5β1 integrin and achieved increased gene expression 
in DLD-1 colorectal cancer cells compared to BJ-fibroblast healthy cells in vitro. 
The multi-targeted system was also able to differentiate between cancer cells 
and healthy cells better than either of the individually targeted systems. In 
addition, we constructed a novel cancer therapeutic plasmid by cloning a highly 
potent diphtheria toxin fragment A (DTA) expressing gene under the control of an 
NF-κB responsive element (pNF-κB-DTA). A dose-dependent reduction of 
cellular protein expression and increased cytotoxicity in cancer cells was seen 
when transfected with PR_b functionalized stealth liposomes encapsulating the 
condensed pNF-κB-DTA plasmid. Our therapeutic delivery system specifically 
eradicated close to 70% of a variety of cancer cells while minimally affecting 
healthy cells in vitro. Furthermore, the modular nature of the non-viral design 
allows targeting novel pairs of extracellular receptors and upregulated 
transcription factors for applications beyond cancer gene therapy. 
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5.2 Introduction 
A major problem facing cancer therapy is non-specific delivery of administered 
therapeutics. The non-specific accumulation in healthy sites can often result in 
undesirable toxic side effects, necessitating the development of delivery vectors 
that can limit off-target cytotoxicity. A significant portion of the delivered 
therapeutic dose is taken up by the macrophagocytic system (MPS) leading to 
subsequent accumulation in the liver and the spleen. One strategy to address 
this issue is the encapsulation of therapeutics in nanoparticles functionalized with 
a polyethylene glycol (PEG) brush layer, which can help tumor accumulation by 
increasing circulation lifetime and the enhanced permeation and retention 
effect.7,54 In addition, targeting ligands can be incorporated on the nanoparticle 
surface to bind to extracellular receptors overexpressed in tumor tissue and 
vasculature181,196,200,219 thereby facilitating internalization into target cells.3 While 
PEGylation and targeting can improve delivery efficiency compared to traditional 
delivery of free therapeutics, these systems continue to experience significant 
MPS uptake29 Also, many widely investigated cancer cell or cancer vasculature 
receptor targets such as integrins,30 the endothelial growth factor receptor31 and 
fibroblast growth factor receptor 32 are also appreciably expressed in healthy 
tissues and vasculature.33–35 These issues can lead to the same non-specific side 
effects that targeted therapy is striving to avoid, and call for further levels of 
control to minimize non-specific delivery.220  
Gene therapy is becoming an increasingly popular form of cancer treatment. One 
way gene therapy can solve the problem of non-specific delivery is through the 
addition of transcriptional targeting to the extracellular receptor targeting that is 
already in place, generating a multi-targeted system for better control of gene 
expression. Transcriptional targeting has been widely investigated in the past, 
and has been shown to improve specific delivery to the target tissues.36,37 
Generally, transcriptional targeting involves delivering a gene under the control of 
a tissue specific promoter – allowing gene expression in target tissues while 
avoiding healthy areas. Multi-targeting by combining transductional and 
transcriptional targeting has been shown before to effectively increase the 
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specificity of a viral gene delivery system,38–40 however it has not been sufficiently 
investigated in a non-viral delivery system.41 Non-viral systems offer several 
advantages over viral gene delivery vectors – they are tunable, safer, cheaper 
and easier to build.6,221 The tunable nature of these systems can facilitate the 
construction of a modular multi-targeted system.  
A second major problem in cancer therapy is the development of resistance to 
chemo and radiation therapies in cancer cells, rendering these traditional forms 
of treatment largely ineffective. NF-κB is a well-characterized group of 
transcription factors that are upregulated in a variety of diseases including 
cancer42 and is known to mediate resistance to chemotherapy and radiation 
therapy.43 Inhibition of NF-κB activity has been shown to improve cancer therapy 
by reducing NF-κB mediated chemotherapy resistance.44 However, its 
transcriptional activity has never been used as a therapeutic target before. Given 
the central role played by NF-κB as a transcription factor controlling a variety of 
cancer progression pathways, we postulated that its upregulated activity would 
be sufficient to mediate a therapeutic response specifically in cancer cells. In 
addition, targeting the transcriptional activity of a single upregulated transcription 
factor may offer better control and outcome predictability compared to 
conventional transcriptional targeting using entire promoter sequences of 
upregulated genes.  
In this paper, we took advantage of the versatility of gene therapy and developed 
a multi-functional therapeutic system. As a delivery vehicle we chose PR_b 
functionalized stealth liposomes encapsulating branched polyethyleneimine 
(bPEI) condensed plasmid DNA (pDNA), a non-viral gene delivery vehicle 
recently development in our group to specifically transfect α5β1 integrin bearing 
cells.202 The PR_b targeting ligand used in this system is a fibronectin mimetic 
peptide developed by our group to preferentially bind α5β1 integrin with an affinity 
of 76.3±6.3 nM,17,195 and has since been used to improve nanoparticle delivery to 
α5β1 integrin bearing cells for a variety of applications.19,21,185,203,204,222 PR_b 
functionalized nanoparticles can outperform other RGD based peptide 
functionalized nanoparticles, and can distinguish between cells with differential 
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expression levels of α5β1 integrin.20,186 α5β1 integrin is a widely accepted and 
well-investigated cancer surface marker.14 It is highly expressed on embryonic 
cell types but it is downregulated during development.16 It is also highly 
upregulated in tumor vasculature and in tumor cells of breast and prostate cancer 
and, central to this work, colorectal cancer.14,15 However, α5β1 integrin is also 
present in normal tissues such as hepatic sinusoids, endothelial venules of lymph 
nodes, pancreatic ducts and intestinal smooth muscle, even though most of 
these healthy sites are not accessible from the bloodstream.33 For example, 
intravenously injected anti-α5β1 antibody examined the amount and distribution of 
the integrin present in vivo and this study revealed that the injected antibody 
strongly labeled tumor vessels but did not label most normal blood vessels and 
did not access pancreatic ducts or intestinal smooth muscle.33 However, hepatic 
sinusoids and lymph nodes remain vulnerable to non-specific transfection.33  
We hypothesized that by adding a second level of control to PR_b functionalized 
stealth liposomes via transcriptional targeting, we can improve the specificity of 
cancer cell transfection while minimizing off-target effects. We therefore targeted 
the upregulated transcriptional activity of NF-κB as a new form of transcriptional 
targeting, and showed increased cancer specificity. In addition, to address the 
problem of low gene expression mediated by most transcriptional targeting, we 
chose the highly potent diphtheria toxin fragment-A (DTA) as the protein product 
of gene expression. DTA consists of only the catalytic fragment of diphtheria 
toxin and lacks a cell-penetrating domain, which can minimize any bystander cell 
killing effect at off-target sites. A few molecules of DTA can be enough to result in 
cell death through inhibition of protein expression45 and DTA-encoding plasmids 
have been previously used to successfully kill cancer cells.36,46 Moreover, some 
healthy cell lines have been previously shown to be resistant to DTA activity,45 
which further augments the potential cytotoxic specificity of our design. Thus, by 
delivering a DTA gene under the regulation of a NF-κB responsive element, we 
showed that the high transcriptional activity of NF-κB in cancer cells can mediate 
specific cytotoxicity in a variety of cancer cells compared to healthy cells in vitro.  
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By combining the targeting of two well-recognized cancer markers, α5β1 integrin 
and upregulated NF-κB transcriptional activity, we created a general, modular 
platform for cancer-specific transfection agents. This multifunctional design may 
also offer a solution to NF-κB mediated cancer resistance to chemotherapy and 
radiation therapy, and can be a useful adjuvant to increase the efficiencies of 
these traditional forms of cancer treatment.  
5.3 Materials and Methods 
5.3.1 pNF-κB-DTA construction 
pNF-κB-Luc (Agilent, Santa Clara, CA) was sequenced at the University of 
Minnesota Genomics Center (UMGC) with a Luc-B1 primer according to the 
manufacturer’s instructions. We verified the presence of the NF-κB binding 
domain, 10 bp tandem repeats of GGGGACTTTC, and identified the region of 
interest between the promoter and the transcription start site to help determine 
an insertion site for the diphtheria toxin fragment A (DTA) gene. The gene 
sequence coding for DTA 223 was designed and manufactured in GeneArt (Life 
technologies, Grand Island, NY). In order to keep the NF-κB responsiveness of 
the plasmid the same, the DTA gene (Life Technologies, Grand Island, NY) was 
inserted exactly in place of the luciferase gene, maintaining the minimal promoter 
region. DTA was cloned into the pNF-κB-Luc plasmid using an In-Fusion HD 
cloning kit according to the manufacturer’s protocol (Clontech, Mountain View, 
CA). We first PCR-amplified the DTA gene with primer overhangs 
complementary to the 16 bp region on either side of the corresponding insertion 
sites on the pNF-κB-Luc plasmid. Forward primer 
(ATGGAAGCTCGAATTCCAGCTTGGCA) and reverse primer (TTGTAACA 
ATATCGATTCATCTCCGCACTCTGTTG) used in this experiment were 
manufactured at UMGC. The PCR amplified product was verified using gel 
electrophoresis and sequencing at the UMGC facilities. EcoRI and ClaI restriction 
enzymes (Invitrogen supply cabinet, University of Minnesota) were used to 
linearize the pNF-κB-Luc plasmid following the New England Biolabs (Ipswich, 
MA) protocols. The linearization process was verified using gel electrophoresis. 
DTA insert was ligated with the linearized pNF-κB-Luc plasmid using the In-
	   82	  
Fusion HD cloning kit according to the manufacturer’s instructions. The reaction 
products were transformed into a Top10 Ecoli strain (Invitrogen, Grand Island, 
NY) and plated on LB-Amp media. Colony PCR was performed on the bacterial 
colonies the next day with primers NF-κBDTA-F GGCAGCAGCAGCGTGGAGTA 
and NF-κBDTA-R CAGGCCTGGGCCATATATCGT (UMGC) against the DTA 
gene. Out of the eight colonies tested, one appeared to have a plasmid bearing 
the DTA gene. The colony was amplified and the plasmid harvested using a 
Plasmid Miniprep kit (Qiagen, Valencia, CA). Presence of DTA gene in the 
plasmid in the correct position and orientation was verified at the UMGC DNA 
sequencing facilities.  
5.3.2 Liposome synthesis 
1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dipalmitoyl-sn-glycero-
3-phosphoethanol amine-N-[methoxy(polyethylene glycol)-2000] (ammonium 
salt) (DPPE-PEG2000), and cholesterol were purchased from Avanti Polar 
Lipids, Inc (Alabaster, AL). PR_b peptide was purchased from UMGC and 
amphiphiles were synthesized as previously described.17 PR_b functionalized or 
non-targeted stealth liposomes were made using a thin film lipid hydration 
method. Briefly, a mixture of lipids containing x mol % PR_b peptide-amphiphiles, 
5 mol % DPPE-PEG2000, (60-x) mol % DPPC and 35 mol % cholesterol were 
deposited in a round bottom flask and dried under a stream of argon (x =0 for 
non-targeted stealth liposomes and 5 for PR_b functionalized stealth liposomes). 
Plasmid DNA was condensed with branched polyethylenemine (bPEI) as 
previously described (section 4.3.1), and used to hydrate the lipid film for 2 h in a 
water bath held at 45 ᵒC. The hydrated liposomes were then extruded through 
400nm polycarbonate membranes in a hand held extruder (Avestin, Ontario, CA). 
Extruded liposomes were dialyzed against water for 24 h in a 1000 kDa MWCO 
dialysis membrane (Spectrum Labs, Rancho Dominguez, CA) with frequent water 
changes. pDNA concentration in the liposomes was then measured using a cy5 
DNA quantification assay (Mirus Biosciences, Madison, WI) as described 
previously (Section 3.3.3). 
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5.3.3 Flow cytometry to detect α5β1 integrin 
DLD-1 human colorectal cancer cells and human BJ fibroblasts (ATCC, 
Manassas, VA) were cultured in T75 flasks in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% fetal bovine serum and 10% of a 10,000 
units/ml penicillin – 10 mg/ml streptomycin solution (Sigma Aldrich, St Louis, 
MO), at 37 °C and 5% CO2 to 70-80% confluence.  Cells were harvested and 
resuspended at 1x106 cells/ml in 500 μl of 4 °C fluorescent buffered saline (FBS, 
2 w/v% BSA in PBS buffer), and incubated with 10 μg MAb1969 (Millipore, 
Billerica, MA) mouse anti-human α5β1 antibody or 5 μg 119K7690 (Sigma-Aldrich, 
Saint Louis, MO) mouse isotype control for 30 min at 4 °C on a rotary shaker. 
Cells were pelleted by centrifugation and washed twice with 1 ml of 4°C FBS and 
incubated with 40 μg of AP124F (Millipore, Billerica, MA) goat anti-mouse 
fluorescent secondary antibody for 30 min at 4 °C on a rotary shaker. Following 
incubation, cells were pelleted by centrifugation, washed twice with 4 °C FBS and 
analyzed immediately on a FACScalibur flow cytometer (Masonic cancer center, 
University of Minnesota). 
5.3.4 RT-PCR for NF-κB mRNA 
DLD-1, BJ fibroblasts, or HEK293T cells (gift from Prof. McIvor, University of 
Minnesota, uninduced or induced with 20 ng/ml TNF-α) were grown on DMEM at 
37 °C and 5% CO2 to 70-80% confluence in a 6 well plate. Manufacturer’s 
protocols were followed for mRNA harvest using an RNeasy extraction kit 
(Qiagen, Valencia, CA) for cDNA generation using RNA to cDNA ecodry premix 
(Clontech, Mountain View, CA), and for running PCR on a Stratagene MX3000P 
using SYBR advantage PCR kit (Clontech, Mountain View, CA). The following 
PCR primer pairs were identified in NCBI primer blast, manufactured at UMGC 
and used for the detection of different NF-κB proteins: h-NF-κB1-F 
GTGCAGAGGAAAC GTCAGAAGC, h-NF-κB1-
R CCGCCACTACCAAACATGCC, h-NF-κB2-F AGACAACCTCACCCAGTGGC, 
h-NF-κB2-R CTCGGGTTTCTGGACCCCTC, h-cRel-F 
CTCCGGTGCGTATAACCCGT, h-cRel-R CTGTGCTCCCCTGGAATGCT, h-
RelA-F AAGAGCAGCGTGGGGACTAC, h-RelA-R 
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CAGTGTTGGGGGCACGATTG, h-RelB-F CCTCGCGAC CATGACAGCTA, h-
RelB-R CCAGGATGGCCGGCTTTTTC. Human β-actin was used as a 
housekeeping gene control with primers h-Actin-F 
TGAGACCTTCAACACCCCAG and h-Actin-R AGATGGGCACAGTGTGGGT. 
The relative amount of NF-κB mRNA was calculated relative to the geometric 
mean of the cycle thresholds of the housekeeping gene β-actin using the 2-ΔΔCt 
method.224 
5.3.5 Luciferase transfection and luminescence measurement 
DLD-1 colorectal cancer cells and BJ fibroblast skin cells were plated at 5000 
cells per well in a clear 96 well plate in 200 μl of DMEM. Medium was 
replenished the next day and cells transfected with 100 to 250 ng of pDNA 
encapsulated in different liposomes. The liposome formulations tested were 
PR_b functionalized stealth liposomes encapsulating either pNF-κB-DTA plasmid 
or the pT2/Cal plasmid, and non-targeted stealth liposomes encapsulating pNF-
κB-DTA. Liposomes were incubated with the cells for a period of 72 h in an 
incubator at 37 ᵒC and 5% CO2. Cells were then washed in PBS buffer, media 
was replenished and the WST-1 assay (Promega, Madison, WI) was used to 
measure cell viability according to the manufacturer’s protocol. Cell viability is 
reported as a percentage of untransfected cells.  For experiments demonstrating 
the versatility of the pNF-κB-DTA plasmid, MCA38 murine colon cancer cells, 
MCF7 human breast cancer cells and TNF-α induced HEK293T human 
embryonic kidney cells were similarly transfected with 100 ng pNF-κB-DTA in 
PR_b functionalized stealth liposomes with pmaxGFP as the control. For 
experiments investigating the effect of DTA dosage on cell viability, different 
concentrations of pNF-κB-DTA in PR_b functionalized stealth liposomes were 
delivered to DLD-1 cells, with pMaxGFP as the control. Cell incubation and cell 
viability measurements were carried out as described above.  
5.3.6 RT-PCR for DTA mRNA 
DLD-1 cells were seeded in a 6 well plate at 1x105 cells/well in 1ml DMEM media 
and cultured at 37 °C and 5% CO2.  24 h later, medium was replenished and 
pNF-κB-DTA encapsulated in PR_b functionalized or non-targeted stealth  
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Figure 27. Relative levels of α5β1 integrin expression in DLD-1 cells and BJ-
fibroblasts.  
Cells were incubated with a mouse anti-human α5β1 integrin antibody, followed by 
incubation with a FITC labeled goat anti mouse antibody. Cells were then sorted for FITC 
label on flow cytometry. Data present mean ± standard error for three independent 
experiments (n=3), done in triplicate. Students t-test statistical analysis was performed, * 
indicates p<0.001. 
liposomes was used to transfect the cells at 1 μg/well. Following incubation for 24 
h more, manufacturer’s protocol was followed for mRNA harvest using an 
RNeasy extraction kit (Qiagen, Valencia, CA), for cDNA generation using RNA to 
cDNA ecodry premix (Clontech, Mountain View, CA), and for running PCR on a 
Stratagene MX3000P using SYBR advantage PCR kit (Clontech, Mountain View, 
CA). The following PCR primer pairs were manufactured at UMGC and used for 
the detection of DTA mRNA: NF-κB-DTA-F GGCAGCAGCAGCGTGGAGTA and 
NF-κB-DTA-R CAGGCCTGGGCCATATATCGT. Human β-actin was used as a 
housekeeping gene control with primers h-Actin-F 
TGAGACCTTCAACACCCCAG and h-Actin-R AGATGGGCACAGTGTGGGT. 
The relative amount of DTA mRNA was calculated relative to the geometric mean 
of the cycle thresholds of the housekeeping gene β-actin using the 2-ΔΔCt 
method.224 
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Figure 28. NFκB mRNA levels in (A) DLD-1 cells relative to BJ-fibroblasts and (B) 
TNF-α induced versus uninduced HEK293 cells. 
mRNA harvested from cells was probed for the presence of RelA, RelB, cRel, NF-κB1 
and NF-κB2 using RT-PCR, with beta-actin mRNA as a housekeeping gene control. Data 
presented as mean ± standard error for nine independent experiments (n=9), done in 
triplicate. 
 
5.4 Results 
5.4.1 Expression of α5β1 integrin and NF-κB in cancer cells compared to 
healthy cells 
We hypothesized that in situations where a cancer-related extracellular target 
receptor is also overexpressed in healthy cell lines, further levels of control would 
be needed for cancer specific gene delivery. For that we used DLD-1 colorectal  
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cancer cells and BJ fibroblast that express the α5β1 integrin at a higher level than 
DLD-1 cancer cells (Fig. 27). BJ fibroblasts are primary fibroblasts from the 
foreskin of a newborn and α5β1 is highly expressed in embryonic cell types while 
it is downregulated during development in adult tissues. While this primary cell 
line is not likely to be encountered by gene delivery vehicles administered in vivo 
in an adult, it serves as a useful model for healthy cells expressing the receptor 
of choice. The relative expression levels demonstrate a scenario where the first 
level of extracellular receptor targeting by itself would be unable to differentiate 
between healthy cells and cancer cells, leading to undesirable side effects in off 
target cells. To identify a model for the second level of intracellular targeting that 
would increase specificity of gene delivery to cancer cells, we chose to 
investigate the transcription factor NF-κB that is strongly implicated in the 
development and progression of cancer. NF-κB can exist in several different 
forms in cells – as homo or heterodimers of RelA, RelB, cRel, NF-κB1 or NF-
κB2.42 mRNA levels of NF-κB in DLD-1 cells and BJ fibroblasts were measured 
using RT-PCR and four out of the five NF-κB proteins tested were seen to be 
upregulated in DLD-1 colorectal cancer cells compared to the healthy BJ 
fibroblasts (Fig. 28A). To further validate the differential NF-κB expression in 
healthy versus cancer or NF-κB-induced cells, NF-κB expression levels were 
investigated in normal or TNF-α induced human embryonic kidney HEK293T 
cells, as TNF-α inflames HEK293T cells and induces NF-κB activation. NF-κB 
levels were also seen to be upregulated in induced HEK293T cells compared to 
uninduced cells (Fig. 28B). In some of our subsequent experiments normal or 
TNF-α induced HEK293T cells were used as a supplementary model to further 
demonstrate NF- κB mediated gene expression. Thus NF-κB is an intracellular 
target that could be utilized successfully to differentiate between healthy and 
diseased cells and in particular the DLD-1 cells and BJ fibroblasts that are used 
here as a cancer and healthy cell model for therapeutic delivery. 
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Figure 29. Luciferase expression in DLD-1 cells or BJ fibroblasts.  
PR_b functionalized stealth liposomes or stealth liposomes were used to transfect 
pT2/Cal plasmid (luciferase under a constitutive CAGS promoter), pNF-κB-Luc (luciferase 
under NF-κB responsive element) or pLucMCS (promoterless luciferase plasmid) in DLD-
1 cells or BJ fibroblasts, and luminescence from luciferase expression measured after a 
48 h incubation at 37°C. Data presented as mean ± standard error from three 
independent experiments (n=3), done in triplicate. Students t-test statistical analysis was 
performed, bracketed data indicates p<0.05; absence of brackets for p>0.05. 
 
5.4.2 Multi-targeting increases specificity of luciferase gene expression in 
cancer cells compared to healthy cells 
To demonstrate increased specificity with the multi-targeting approach DLD-1 
cells and BJ fibroblasts were transfected with two different plasmids – pT2/Cal, 
that constitutes the luciferase gene under the control of a CAGS constitutive 
promoter,187 or pNF-κB-Luc, where the luciferase gene is controlled by an NF-κB 
responsive element. The plasmids were condensed with bPEI and encapsulated 
in either PR_b functionalized or non-targeted stealth liposomes. In both cases, 
non-targeted stealth liposomes resulted in low transfection levels, demonstrating 
the effectiveness of the first level of extracellular targeting (Fig. 29). When 
pT2/Cal was delivered to these cells using PR_b functionalized stealth  
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Figure 30. Luciferase expression in TNF-α induced or uninduced HEK293T cells.  
Cells were transfected with 100ng of pT2/Cal plasmid (luciferase under a constitutive 
CAGS promoter), pNFκB-Luc (luciferase under NFκB responsive element) or pLucMCS 
(promoterless luciferase plasmid) encapsulated in PR_b functionalized stealth liposomes 
or stealth liposomes, and luminescence from luciferase expression measured after a 
48hour incubation at 37°C. Data presented as mean ± standard error from three 
independent experiments (n=3), done in triplicate. Students t-test statistical analysis was 
performed, * indicates p<0.05, ** p<0.005, absence of brackets for p>0.05. 
 
liposomes, both DLD-1 and BJ-fibroblasts expressed the luciferase gene at very 
similar levels. This demonstrates a crucial element of our hypothesis – namely 
the inability to differentiate between cancer cells and healthy cells with a single 
level of extracellular targeting in situations where the extracellular receptor is 
upregulated in off-target tissues. These results also show similar transfection 
efficiencies between these two cell lines, thereby justifying a fair comparison. In 
contrast, when pNF-κB-Luc was delivered to these cells with PR_b functionalized 
stealth liposomes, DLD-1 cells maintained similar levels of luciferase expression 
compared to pT2/Cal transfection, while expression in healthy BJ fibroblasts 
dropped to control levels as seen in the case where plasmids were delivered  
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Figure 31. Schematic of A) pNF-κB-Luc and B) pNF-κB-DTA  
The common DNA sequence showing the promoter region and transcription start site for 
A) and B) is presented below. 5 tandem repeats of a 10 bp NF-κB responsive element, 
EcoRI restriction site, and transcription start site are shown in red. pNF-κB-DTA was 
constructed by cloning the DTA gene between the EcoRI and ClaI sites in pNF-κB-Luc.  
 
using non-targeted stealth liposomes. Therefore, introducing a second level of 
intracellular targeting significantly increased specificity of gene expression in 
cancer cells. To further prove that the luciferase expression seen after 
transfection with pNF-κB-Luc was due to the activity of NF-κB, the pLuc-MCS 
plasmid was used as a control, which is the same plasmid lacking the NF-κB 
responsive element. Luciferase expression was not detectable in either cell line, 
relating any measurable expression to NF-κB transcriptional activity. With almost 
two orders of magnitude difference between the levels of gene expression in 
DLD-1 cells versus BJ fibroblasts, we concluded that using a multi-targeted 
approach holds promise for cancer-specific gene therapy. In addition, this 
experiment was repeated using HEK293T cells in their uninduced and induced 
forms to demonstrate that multi-targeting can increase specificity in other 
diseases where NF-­‐κB	  levels	  are	  upregulated. Gene expression trends were similar 
(Fig. 30). 
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Figure 32. DTA mediated cytotoxicity in DLD-1 cells and BJ fibroblasts.  
250 ng of bPEI condensed pNF-κB-DTA or pT2/Cal encapsulated in PR_b functionalized 
or non-targeted stealth liposomes were used to transfect cells for 72 h at 37 °C, followed 
by measuring cell viability using a WST-1 metabolic assay and shown as a percentage of 
untreated samples. Data presented as average ± standard error of three independent 
experiments (n=3), done in triplicate. Student’s t-test statistical analysis was performed, * 
indicates p<0.05, ** p<0.005, absence of brackets for p>0.05. 
 
5.4.3 Multi-targeting can specifically eradicate cancer cells while sparing 
healthy cells 
To investigate the therapeutic potential of the multi-targeted gene delivery 
system, we designed a cancer specific suicide gene therapy regime. As a 
cytotoxic gene of interest we chose the DTA encoding gene, which has been 
previously shown to effectively kill cancer cells.225,226 pNF-κB-DTA (Fig. 31) was 
created by cloning in the DTA gene in the place of the luciferase gene in pNF-κB-
Luc. To show cancer specific therapy, pNF-κB-DTA was delivered into DLD-1 
cells and BJ-fibroblasts with PR_b functionalized or non-targeted stealth 
liposomes (Fig. 32). As a control, these cells were transfected with pT2/Cal in 
PR_b functionalized stealth liposomes. Successful cytotoxic therapy was  
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Figure 33. DTA mediated inhibition of protein expression in DLD-1 cells.   
5 mol % PR_b functionalized stealth liposomes were used to transfect cells with 100 ng 
of pT2/Cal plasmid and different amounts of pNF-κB-DTA or pmaxGFP for 48 h at 37 °C. 
Luminescence was measured with a luciferase expression assay kit and reported as a 
percentage of expression from control cells that received only the pT2/Cal plasmid. Data 
presented as average ± standard error of three independent experiments (n=3), done in 
triplicate. Student’s t-test statistical analysis was performed, * indicates p<0.05, ** 
p<0.005, absence of brackets for p>0.05. 
 
observed only when PR_b functionalized stealth liposomes were used to 
transfect pNF-κB-DTA in DLD-1 colorectal cancer cells, that is when both levels 
of targeting were used and both targets were upregulated in the cells. While more 
than 60% of cancer cells were killed, on average only 15% of the healthy cells 
were affected. This low level of non-specific cell cytoxicity is thought to be a 
result of a combination of DTA expression from background NF-κB activity and 
cytotoxicity from the bPEI used to condense the pDNA. 
5.4.4 Further characterization of DTA activity 
To relate the cytotoxic effect seen in the cancer cells to DTA production, we 
further investigated the effect of delivering pNF-κB-DTA to DLD-1 cancer cells  
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Figure 34. Cytotoxic dose response to increasing pNFκB-DTA delivery.  
DLD-1 cells were transfected with different amounts of pNF-κB-DTA or pmaxGFP 
encapsulated in 5 mol% PR_b functionalized stealth liposomes for 72 h at 37 °C. Cell 
viability was measured using WST-1 metabolic assay and reported as a percentage of 
the viability of untreated cells. Data presented is average ± standard error of four 
independent experiments (n=4), done in triplicate. Student’s t-test statistical analysis was 
performed, * indicates p<0.05, ** p<0.005, absence of brackets for p>0.05. 
 
using several different techniques. First, RT-PCR was used to measure the 
amount of DTA mRNA produced in DLD-1 cells after transfection with pNF-κB-
DTA using PR_b functionalized or non-targeted stealth liposomes. DTA mRNA 
was detected in transfected cells and the levels were 4.5 ± 0.6 times (Ave ±	  SD	  
from n=3, done in triplicate) higher when PR_b functionalized stealth liposomes 
were used versus non-targeted stealth liposomes. This explains the low level of 
cytotoxicity seen when DLD-1 cells are transfected with pNF-κB-DTA 
encapsulated in non-targeted stealth liposomes, and shows the control over gene 
expression exerted by the first level of our multi-targeting approach – targeting 
the extracellular α5β1	  integrin.	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Second, to investigate the mode of action of DTA in killing cells we measured 
protein expression after transfecting DLD-1 cells with pNF-κB-DTA encapsulated 
in PR_b functionalized stealth liposomes. DTA is thought to cause cell death by 
inhibiting protein expression.227 DLD-1 cells were co-transfected with pT2/Cal and 
pNF-κB-DTA and luciferase expression was measured relative to cells that 
received only pT2/Cal (Fig. 33). Co-transfection with pmaxGFP, a GFP 
expressing plasmid, was used as a control.  A dose dependent reduction in 
luciferase expression was seen with the delivery of increasing amounts of pNF-
κB-DTA. A substantial level of protein inhibition was observed even at 25 ng of 
pNF-κB-DTA delivered, the lowest amount of DNA delivery investigated in the 
current studies. When 250 ng of pNF-κB-DTA was delivered we observed 
instances where the level of protein expression went down below detectable 
levels.  
Third, to complement these protein expression inhibition studies we measured 
the effect of DNA dosage on cytotoxicity in DLD-1 cells. With increasing amounts 
of pNF-κB-DTA delivered in PR_b functionalized stealth liposomes, increased 
cytotoxicity was seen (Fig. 34). There was no corresponding trend observed 
when pmaxGFP was used as a control, showing on average less than 10% non-
specific cytoxicity at all pDNA concentrations delivered. Interestingly, cytotoxicity 
was not observed in DLD-1 cells at 100 ng of pNF-κB-DTA delivered, an amount 
which resulted in 82.5±0.5% protein inhibition (Fig. 33). Our results therefore 
suggest that protein production may need to be completely halted before 
cytotoxicity results in DLD-1 cancer cells.  
5.4.5 pNF-κB-DTA is a versatile plasmid capable of killing a variety of 
cancer types 
We also wanted to investigate the versatility of the pNF-κB-DTA plasmid in killing 
different types of cancer and diseased cells. To this end, pNF-κB-DTA 
encapsulated in PR_b functionalized stealth liposomes was delivered to MCA38 
murine colon cancer cells, MCF7 human breast cancer cells, and TNF-α induced 
HEK293T human embryonic kidney cells while using pmaxGFP as a control. In 
all these cell lines, a high level of cytotoxicity was observed after transfection with  
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Figure 35. Demonstrating versatility of pNF-κB-DTA 
A) DTA mediated cytotoxicity in MCA38 murine colon cancer cells, MCF7 human breast 
cancer cells and TNF-α induced HEK293T human embryonic kidney cells. 100 ng of 
pNF-κB-DTA or pmaxGFP encapsulated in 5 mol% PR_b functionalized stealth 
liposomes were used to transfect cells for 72 h at 37 °C, followed by measuring cell 
viability using a WST-1 metabolic assay as a percentage of untreated samples. B) DTA 
mediated inhibition of protein expression in MCA38 cells, MCF7 cells and TNF-α induced 
HEK293T cells. 5 mol% PR_b functionalized stealth liposomes were used to transfect 
cells with 100 ng of pT2/Cal plasmid and 100 ng of pNF-κB-DTA or pmaxGFP for 48 h at 
37 °C. Luminescence was measured with a luciferase expression assay kit and reported 
as a percentage of expression from control cells that received only the pT2/Cal plasmid.  
Data presented is average ± standard error of three independent experiments (n=3), 
done in triplicate. Student’s t-test statistical analysis was performed, ** indicates p<0.005. 
 
pNF-κB-DTA compared to the control (Fig. 35A). Furthermore, for each of the cell 
lines tested DTA was shown to inhibit protein production (Fig. 35B). Taken 
together, these results demonstrate the versatility of pNF-κB-DTA in killing 
cancer cells and TNF-α induced HEK293T cells. Also, pNF-κB-DTA was able to 
kill MCA38, MCF7 and HEK293T induced cells effectively at only 100 ng delivery, 
in contrast to the higher amounts required for DLD-1 cells. This is likely due to 
differences in transfection efficiency and differential effectiveness of DTA in 
different cell lines.45 
5.5 Discussion 
In this paper we focused on the problem of specific delivery of non-viral gene 
delivery vehicles to cancer cells versus healthy cells in vitro. However, the same 
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problem of off target extracellular receptor expression is prevalent in other 
therapeutic strategies. For example, an exciting new development in gene 
therapy is reengineered T cells that can be specifically activated upon interaction 
with the CD19 receptor found on B cell lymphomas.228 Unfortunately, CD19 is 
also expressed on normal B cells.229 Similarly, myelodysplastic syndrome 
associated stem cells that progress into amyeloid leukemia offer no 
distinguishing extracellular receptors compared to normal cells.230 In situations 
like these, a multi-targeted therapeutic system could aid recognition of and 
therapeutic delivery into target cells and subsequently transcriptionally control the 
expression of a desired gene therapy product. 
The regulation of gene expression in mammalian cells however is a complex 
process. Tumor specific promoters may be regulated by many different 
transcriptional components. For example, tumor specific promoters previously 
used in transcriptional targeting such as survivin and H19 86,231 are regulated by 
the SP1, E2F, and C/EBP families of transcription factors and their 
cofactors.232,233 The involvement of multiple transcription factors and regulatory 
components may substantially increase the noise in gene expression.234 While 
noise in gene expression can be useful in regulatory events in the cell, it can also 
lead to unpredictable heterogeneous outcomes following uniform inputs.235 
Therefore, the simplicity of a design where gene expression is mediated by a 
single upregulated transcription factor may be attractive for building more 
controllable and predictable gene delivery vectors. A similar effect can be 
obtained by trimming full promoters of upregulated genes to the bare minimum 
essential for transcription, as was done for HIF-1α.236 In our design, expression 
of DTA is regulated by five tandem repeats of a 10 bp NF-κB responsive element 
(Fig. 31). 
We developed a multi-targeted gene delivery system combining extracellular 
receptor targeting and transcriptional targeting and showed improved specificity 
of gene expression in cancer cells compared to healthy cells in vitro. The PR_b 
peptide targets the α5β1 integrin receptor and allows for subsequent 
internalization of the nanoparticles and release of the payload by cells that 
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overexpress the integrin compared to non-targeted stealth liposomes (Figs. 29 
and 32). Previous work in our group showed that PR_b functionalized 
nanoparticles bind with high specificity to α5β1 and internalization of PR_b 
functionalized vesicles was absent on cells where the integrin was minimally 
expressed.186,204 We further showed that the strategy of using a second level of 
control for gene expression can successfully relieve the problems of non-
specificity faced by current extracellular receptor targeted gene delivery vectors. 
The increased transcriptional activity of NF-κB in cancer cells versus healthy 
cells (Fig. 28A) resulted in a twenty-fold increase in luciferase expression (Fig. 
29) and substantial cytotoxicity in DLD-1 colorectal cancer cells compared to 
healthy BJ fibroblast cells (Figs. 32 and 34). Furthermore, the lack of detectable 
gene expression in the absence of this NF-κB binding element demonstrates the 
strict control over gene expression exerted by a single transcription factor (Fig 
29). The versatility of the constructed pNF-κB-DTA plasmid was demonstrated by 
successfully inhibiting protein expression and inducing apoptosis in DLD-1 
human colorectal cancer cells, MCA38 murine colon cancer cells, MCF7 human 
breast cancer cells and TNF-α induced HEK293T human embryonic kidney cells 
(Fig. 35). While the inhibition of protein expression seemed to be similarly 
effective in all cell lines tested (Figs. 33 and 35B), DLD-1 cells seemed to require 
a higher dose of pNF-κB-DTA for a cytotoxic effect (Fig. 34). This may be an 
indication of differential activity of DTA in different cancer or diseased cell lines.45 
We also noticed a low background level of cytotoxicity (Fig. 32) that could be 
generated by a combination of DTA expression from background NF-κB activity 
and from the bPEI used to condense the pDNA.  
Upregulated NF-κB can be responsible for chemoresistance in cancer.43 Some 
successful cancer therapy strategies involve administering NF-κB inhibitors in 
conjunction to chemotherapy,44,237 where the reduction in cancer 
chemoresistance leads to better treatment outcomes. In contrast, our approach 
uses NF-κB itself to drive therapy in cancer cells and turns cancer cell strength 
into a weakness. For example, in cases where inhibiting NF-κB activity is 
ineffective in promoting cancer therapy,238 targeting NF-κB activity itself to drive 
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therapy can be a potential solution. MCF7 breast cancer cells, one of the cell 
lines that failed to respond to chemotherapy after NF-κB inhibition 238, were 
eradicated with pNF-κB-DTA. This form of NF-κB mediated cancer therapy may 
also have the potential to be an adjuvant to current chemo- and radiation 
therapies. In fact, by identifying and killing NF-κB overexpressing, potentially 
chemoresistant cancer cells, NF-κB mediated therapy may reduce chemo- and 
radiation therapy dosage - thereby alleviating undesirable side effects of these 
traditional forms of therapy.  
Our results demonstrate the potential of driving therapeutic gene expression 
where both with the α5β1 integrin and a single transcription factor, NF-κB, are 
upregulated and warrants further investigation of our design as a new form of 
cancer multi-targeting. One drawback of the current target pair though is that they 
may both be expressed in non-cancerous inflamed tissues, and can therefore 
limit the application of our current delivery system when inflammatory diseases 
(such as rheumatoid arthritis or asthma) and cancer are both present.239,240 
However, with recent advances in high throughput screening and the ability to 
determine cell phenotypes quickly, other cancer specific pairs of extracellular 
receptors and transcriptional targets can be identified.  
5.6 Conclusion 
We designed a modular non-viral multi-targeted gene delivery platform, and 
applied it in the construction of a model system for specific delivery to cancer by 
targeting the overexpressed cancer surface marker α5β1 integrin and the 
upregulated transcriptional activity of NF-κB. We delivered a cytotoxic DTA gene 
using our gene delivery platform and demonstrated specific cytotoxicity in several 
different cancer cell lines while generating minimal non-specific cytotoxicity in 
healthy cells. Our multifunctional design therefore has the potential to 
simultaneously address two major problems facing cancer therapy, namely non-
specificity of gene expression and NF-κB mediated cancer resistance. The 
transcriptional activity of NF-κB warrants further investigation as a therapeutic 
target. Moreover, the versatility of the gene delivery platform developed here can 
facilitate its use in applications beyond cancer.
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Chapter 6. Concluding remarks and future 
directions 
This thesis brings together two separate technologies, self-assembly of 
biomimetic amphiphiles and genetics, and applies them to cancer therapy. The 
observations and conclusions presented here can be used as a guide for future 
work to further advance cancer-specific gene therapy. Through the course of this 
chapter, several modifications to the current design are suggested to improve 
efficiency of gene delivery. Some immediate next steps are outlined, and 
possible long-term future directions are discussed. 
6.1 General contributions to the field 
When seeking receptor targets for gene therapy, the current prevalent 
requirement is overexpression on target tissues. However, results presented in 
Chapter 4 indicate that for successful targeted gene therapy, the optimal 
receptors should possess several other criteria beyond this sole requirement of 
overexpression. Receptors that have fast internalization kinetics and are taken up 
in routes conducive to gene expression are optimal. Adding these criteria to the 
list of optimum receptor properties may lead to the design of more efficient 
transfection agents. In Chapter 4, α5β1 integrin is linked to caveolae-mediated 
endocytosis and a semi-quantitative measure of its internalization kinetics is 
presented for DLD-1 colorectal cancer cells. A collection of similar sets of data, 
for other extracellular receptors in different cell lines, can help in selecting 
appropriate target receptors suited to the application at hand. 
Chapter 4 showed that PR_b functionalized stealth liposomes were internalized 
partially by caveolae-mediated endocytosis, which in turn has previously been 
shown to be involved with transcytosis in endothelial cells in vivo.241–243 It may be 
worth investigating if there is a direct link between α5β1 integrin mediated 
internalization of PR_b functionalized nanoparticles and transcytosis. Many in 
vitro models for investigating transcytosis have been extensively reviewed by 
Tuma and Hubbard,244 and one such experimental model can be adapted to 
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study the uptake of PR_b functionalized vectors. Transcytosing delivery systems 
can be used to treat tumors at their earlier stages, even before they develop the 
extensive, irregular vasculature that is currently essential for the EPR effect. 
Catching and treating cancer early can greatly improve treatment outcome. 
6.2 Design improvements for PR_b functionalized transfection 
agent 
PR_b functionalized stealth liposome have many strengths as a cancer specific 
gene delivery vehicle. Chapter 3 presents its specificity for α5β1 integrin bearing 
cells through in vitro and in vivo experiments; chapter 4 illustrates its high 
stability, fast internalization kinetics, and discusses the benefits it experiences 
from caveolar mediated endocytosis. Unfortunately, this system lacks efficient 
endosomal escape properties, most likely due to ineffective proton sponge effect 
mediated by bPEI. Thus, identifying a cationic polymer that has better endosomal 
release properties can benefit the current design. High throughput screening can 
be used on large combinatorial libraries of polymers with unique properties to 
identify the most desirable candidates.245  
The incorporation of PEG has been previously shown to reduce transfection 
efficiency. However, PEG imparts essential stability to transfection agents, and it 
may be indispensible in an in vivo application. One suggested solution to this is 
the incorporation of PEG on the nanoparticle surface through acid labile linkages 
that are disrupted in the acidic tumor microenvironment. Such acid labile linkages 
can include vinyl ether, orthoester, diorthoester, phosphoramidate, hydrazone 
and β-thiopropionate. Upon losing the PEG layer, the particle surface is exposed, 
thereby increasing the chances of the targeting ligand finding its receptor. In 
addition, once internalized the particle can interact more effectively with the 
endosomal membrane thereby facilitating endosomal release. 
In Chapter 3, the challenges of encapsulating DNA polyplexes in liposomes were 
discussed. While a formulation process to address these challenges was 
outlined, there remains room for improvement. Currently, the average 
encapsulation yield is approximately 40% based on concentration, and 25% 
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based on mass. This is sufficient for the in vitro and the initial in vivo experiments 
presented here, but the inefficiencies can be considerable upon scaling up for 
larger in vivo experiments. Therefore, it may be worth revisiting condensation 
variables in an effort to make polyplexes smaller to improve encapsulation. Yet 
another option may be to replace large plasmid DNA with smaller genetic loads. 
Plasmid DNA, as discussed in Section 2.2.2, often has components not essential 
to therapy, thereby making it larger than necessary. Minicircles and siRNA are 
two other options that have been shown to achieve effective gene therapy.246,247 
Minicircles are minimal expression cassettes, derived from plasmid DNA, that 
lack antibiotic resistance genes, origin of replication and bacterial inflammatory 
sequences; siRNA are 21-23 nucleotide duplexes that can regulate protein 
production by interacting with mRNA in a sequence specific manner and 
hindering translation. Minicircles and siRNA are both are much smaller than 
plasmid DNA, and this can significantly improve liposome encapsulation yields. 
Many of the techniques developed in formulating and characterizing plasmid 
DNA encapsulated liposomes presented in Chapters 3 and 4 can be readily 
applied to the encapsulation of minicircles and siRNA. 
6.3 Further in vivo investigation of PR_b functionalized 
transfection agent 
The ultimate objective of developing tumor specific gene delivery systems is to 
achieve target specific gene delivery in an in vivo setting. Qualitative 
biodistribution data from in vivo experiments presented in Chapter 3 show that 
PR_b functionalized stealth liposomes are a promising non-viral gene delivery 
vehicle. After incorporation of the design improvements suggested above, the 
system should be further investigated in vivo to generate quantitative time-
dependent biodistribution data for nanoparticle localization as well as gene 
expression. Further modifications to the design may be necessary to improve 
cancer specific distribution in an in vivo setting. In particular, PEG length and 
surface concentration, and the inclusion of acid-labile linkages may be some of 
the parameters worth testing. 
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Following in vivo administration of PR_b functionalized nanoparticles, 
immunohistochemistry of organs can yield further information on particle 
distribution at the tissue level. For example, such experiments can be used to 
investigate the depth of tumor penetration. Tumor penetration is a major problem 
in the delivery of therapeutics to tumors.248 In most cases, therapeutics delivered 
within nanoparticles are only able to migrate a certain distance after 
extravasation before being absorbed by the surrounding tissue. This means any 
therapeutic effect is felt within a certain maximum radial distance from the 
supplying blood vessel, and tumor tissue further away receive no treatment. 
PR_b functionalized nanoparticles can be optimized to perform better in vivo by 
characterizing and understanding the barriers faced in tumor penetration. 
6.4 Further investigation of NF-κB transcriptional targeting  
Chapter 5 presents a form of transcriptional targeting not previously investigated. 
Instead of selecting a promoter based on the level of expression of its 
downstream gene, a minimal promoter was chosen based on the level of 
activation of the single transcription factor it binds. Therefore, for the first time, 
the transcriptional activity of a single upregulated transcription factor was used to 
drive therapeutic gene expression specifically in cancer cells. This approach to 
transcriptional targeting adds a useful new tool to the field of gene therapy. 
Chapter 5 also hypothesized several advantages of targeting the activity of a 
single transcription factor, supported by evidence from literature. Experimental 
investigations of these hypotheses may be useful. Specifically, a minimal 
promoter, such as the NF-κB responsive element used in Chapter 5, should be 
compared to a full promoter also responsive to NF- κB for noise level and 
controllability in gene expression. To generalize trends, the comparative 
investigation can be carried out for different transcription factors, regulating 
minimal or full promoters, in a variety of different cell lines. 
The multi-targeted gene delivery system developed in Chapter 5 could effectively 
differentiate between cancer cells and healthy cells bearing the same 
extracellular surface marker, and mediate target specific gene expression. 
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However, a major problem in in vivo administration of nanoparticle delivery 
systems is uptake by the MPS as discussed throughout this thesis. Macrophages 
take up nanoparticles irrespective of the targeting ligand on their surface, so it 
falls to the second level of targeting, i.e. the transcriptional activity of NF-κB in 
this case, to ensure therapeutic genes are not expressed in these cells. It would 
therefore be useful to investigate the expression levels and transcriptional activity 
of NF-κB in an initial in vitro model of macrophages. 
After further optimization of the PR_b functionalized transfection agent in vitro 
and in vivo as described above, the NF-κB regulated plasmid DNA (or minicircle) 
can be encapsulated to generate an optimized multi-targeted gene delivery 
system for in vivo animal model experiments.  The optimal dosing regimen, in 
terms of amount of DNA delivered and frequency of administration should be 
determined for efficient therapy indicated by reduction in tumor growth rate and 
tumor size. Furthermore, the levels and cancer specificity of gene expression 
should be compared between PR_b functionalized stealth liposome 
encapsulating therapeutic genes, such as DTA, under the control of either an NF-
κB responsive element or a constitutive promoter. In vitro, the NF-κB responsive 
element was shown to mediate the same level of gene expression in DLD-1 
cancer cells as a strong constitutive promoter (Fig. 29). It would be interesting to 
see if the effect is maintained in an in vivo setting. 
6.5 Modularity of design 
NF-κB and α5β1 integrin were chosen as cancer-specific targets here as they are 
both well-established markers of cancer. Experiments presented in Chapter 5 
demonstrate the viability of a multi-targeted gene delivery concept in an in vitro 
setting. The two major building blocks in this design, biomimetic peptide 
amphiphiles and genetics, are both tunable technologies. With advances in 
screening and generating peptide libraries, and our increased understanding of 
self-assembly processes, the biomimetic peptide amphiphiles can be tuned for 
diverse applications. Researchers in the life sciences are standardizing genetics 
and genetic manipulation methods, and they have set up a genetic parts registry 
(http://parts.igem.org) that allows mixing and matching of components to create 
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robust gene networks with novel functionalities. The possible modular 
combinations of our two tunable technologies may become virtually limitless as 
these fields continue to advance. Thus, moving forward, the modularity of the 
platform assembled here should allow the targeting of different pairs of 
overexpressed extracellular receptors and upregulated transcription factors, in 
applications medically relevant and otherwise.  
6.6 Final words 
Self-assembled biomimetic amphiphiles and genetics are tunable, flexible and 
modular technologies– and their combinations can result in robust therapeutic 
strategies. This notion is demonstrated here through the development of a novel 
cancer-targeting therapeutic strategy. Biomimimetic peptide amphiphiles were 
combined with transcriptional targeting to create a multi-functional gene delivery 
vehicle that compact and protect DNA, evade the MPS, specifically bind and 
internalize into α5β1 integrin bearing cells, and mediate NF-κB regulated gene 
expression. Genetics and gene delivery may be the keys to the future of 
healthcare. The findings and ideas reported here will be a sturdy foothold from 
which interested researchers can further develop these technologies. 
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